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PTSD AND IMMUNOLOGICAL CORRELATIONS OF ATTENTION AND  
WORKING MEMORY IN GULF WAR ILLNESS 
by 
Mary Jeffrey 
Nova Southeastern University  
ABSTRACT 
Gulf War Illness (GWI) impacts 25 to 32 percent of those deployed in the 1991 Gulf War 
(White et al., 2016) and includes symptoms related to fatigue and mood/neurological 
disturbances. Therefore, it is difficult to ascertain the influence of trauma exposure and 
chemical exposure when investigating neuropsychological symptoms. This cross-
sectional study utilized a group of veterans with and without GWI (n=61) to investigate: 
1) the unique impact that GWI has on a survey measure of attention and memory or the 
Paced Auditory Serial Addition Test (PASAT). We also investigated how PTSD 
symptoms, followed by fatigue levels, improved the GWI model when predicting 
performance. Next, we analyzed the unique impact that GWI diagnosis, followed by pro-
inflammatory interleukins, would have on reported levels of fatigue.  
 
Although there was not a statistically significant relationship between GWI and the 
PASAT scores, there was an emerging trend showing GWI as a meaningful effect. The 
secondary analyses investigating the influence of interleukins on measures of fatigue also 
only showed GWI diagnosis as significant predictor. Post-hoc analyses were conducted 
that included pro-inflammatory (INFγ and TNFα) cytokines in another model of GWI. 
Therefore, a model with the incremental addition of GWI, proinflammatory markers, and 
PTSD symptoms was tested for its ability to predict worse performance on the PASAT. 
Results indicated that pro-inflammatory markers were significant across virtually all trials 
of the PASAT, over and above GWI and PTSD symptom levels. More investigation 
investigating the linkage between these processes and cytokines are therefore necessary 
to elucidate these patterns.  
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Chapter I: Statement of the Problem  
Gulf War Illness (GWI), also known as chronic multi-symptom illness (CMI; 
Fukuda et al., 1998) and Gulf War Syndrome (GWS), impacts 25 to 32 percent of those 
deployed in the 1991 Gulf War (White et al., 2016). GWI varies in case definition. 
Symptoms identified by researchers (Fukuda et al., 1998; Haley, Kurt, & Hom, 1997; 
Steele, 2000) include musculo-skeletal pain (i.e., joint pain, joint stiffness, muscle pain), 
mood/neurological disturbances (i.e., depression, moodiness, anxiety, sleep disturbances, 
memory problems, word-finding difficulties, attention/concentration problems, 
gait/balance disturbances), fatigue, pain, respiratory complaints, and gastrointestinal or 
skin issues. Researchers have identified risk factors leading to GWI, particularly with 
exposure to chemical agents (e.g., pesticides, depleted uranium, chemical nerve agents, 
and pyridostigmine bromide [PB]), as well as exposure to combat-related trauma. 
However, given the retrospective nature of the research, literature remains inconclusive 
regarding the case criterion and etiology of GWI. 
Despite these limitations, research examining the cognitive profile of GWI is 
necessary given that cognitive problems remain one of the most prevalent symptoms 
(Smith et al., 2012; Yee et al., 2016). However, memory problems are endorsed by 71.8 
percent of veterans with GWI, the second most reported symptom followed by fatigue 
(Smith et al., 2012). Overall, neurological, neuropsychological, and physiological 
research has indicated dysfunction in the central nervous system (Steele, 2000; Yee et al., 
2016). However, inconsistent definition of case criteria and measurement have not 
pinpointed definitive trends in cognitive dysfunction. Additionally, research has not 




other relevant factors especially traumatic experiences such as Post-Traumatic Stress 
Disorder (PTSD). Trauma exposure is associated with problems with memory, attention, 
and executive functioning (Koçak & Kiliç, 2017). Also, fatigue is the most common 
symptom reported by GWI and also is associated with cognitive problems in processing 
speed (Tierskey, Johnson, Lange, Natelson, & Deluca, 1997). Therefore, this study 
expanded upon existing literature by investigating how GWI and level of PTSD 
symptoms uniquely contribute to cognitive problems using a neuropsychological measure 
of attention and working memory. We also investigated how fatigue contributes to 
performance on the neuropsychological measure. Additionally, we tested the hypothesis 
that the presence of immunological factors in GWI veterans would be related to measures 
















Chapter II: Review of the Literature 
Gulf War Veterans – Psychogenic Etiology Findings  
In this section, studies are reviewed that examined those deployed in the Gulf War 
and analyzed neuropsychological performance along with psychological distress 
(Axelrod & Milner, 1997; Proctor et al., 2003; Sillanpaa et al. 1997). These researchers 
found evidence of psychogenic underpinnings to Gulf War-related symptoms over 
neurological etiology.  
Axelrod and Milner (1997) tested 44 male veterans who served in Operation 
Desert Storm on a comprehensive neuropsychological exam, self-report questionnaires of 
cognitive symptoms, and psychological questionnaires (see reference for details). 
Participants had an average age of 33.3 (SD = 9.2) and 13.5 years of education; the 
majority of the sample was Caucasian (70%). The veterans were tested against normative 
data. Deficits were evident in two tasks: Grooved Pegboard (Heaton, Grant, & Matthews, 
1992; Matthews & Klove, 1964), and the Stroop Test (Golden, 1978). However, analyses 
returned data indicative of higher psychological distress (as measured by the Minnesota 
Multiphasic Personality Inventory-Second Edition [MMPI-2; Graham, 1990]), associated 
with both measures of cognitive decline. Therefore, Axelrod and Milner (1997) compared 
veterans with and without subjective cognitive complaints. Although results pertaining to 
cognitive deficits remained significant (i.e., Grooved Pegboard, Stroop) in veterans 
reporting cognitive changes, psychological variables were also significant and reported to 
be the stronger finding. Therefore, this study indicated a psychological underpinning to 
cognitive decline. Limitations of this study included a small sample size (n =44) with the 




to the exploratory nature of the project and its impact on reducing significant findings for 
group comparisons (Axelrod & Milner, 1997). Additionally, they reported an effect size 
greater than 0.65 for all t-test analyses. Another limitation pertains to the sample 
consisting of volunteers over a random sample.   
Sillanpaa et al. (1997) investigated neuropsychological and neurological 
functioning in 49 Gulf War Veterans (GWVs). The sample had an average age of 33.59 
years (SD = 9.07), and an average education level of 13.47 (SD = 1.56). The sample was 
predominately Caucasian (69%) and male (90%). Each veteran completed a MMPI-2, 
Symptom Check List-90- Revised (SCL-90-R; Derogatis, 1992), neuropsychological 
symptom checklist (Schinka, 1983), visual analog scale assessing exposure to toxins, 
Neurobehavioral Evaluation System- Continuous Performance Test (CPT; Letz, 1991), 
Grip Strength (Reitan & Davison, 1974), Grooved Pegboard, Neurological Screen (Ross, 
1985), Finger-Tip Number Writing Perception (Reitan & Davison, 1974; Yeudall, 
Reddon, Gill, & Stefanyk, 1987), the Wisconsin Card Sorting Test (WCST; Heaton, 
1981, 1993), Rey Auditory Verbal Learning Test (RAVLT: Lezak, 1983), Wechsler 
Adult Intelligence Scale-Revised (WAIS-R; Wechsler, 1981), and State-Trait Anxiety 
Inventory (STAI; Spielberger, 1983). Additionally, a clinical signs index was created 
from indices of liver enzymes (aspartate amino transferase, alanine amino transferase), 
immune system response (i.e., monocytes), and evidence of infection (i.e., labs and 
clinical examination). Neurocognitive performance was evaluated in comparison to 
normative data. Analyses were conducted to reflect two models. The first model was 
created to reflect variables associated with GWS and included (1) age and education, and 




second model was created to reflect psychological variables and included (1) trait anxiety 
(2) subjective complaints, (3) depression, and (4) state anxiety. The first model did not 
return any significant results once accounting for extraneous variance. However, the 
second model was significant in that psychogenic factors (i.e., trait anxiety, subjective 
complaints, depression, and state anxiety) accounted for more variance in 
neuropsychological performance measuring general cognitive functioning, attention, 
motor coordination, and executive functioning. Therefore, researchers concluded that a 
model of psychological factors better accounted for decline in neurocognitive measures. 
However, limitations of the study included a small sample size (N = 82) which may have 
reduced power. Researchers also noted restricted range and low variance amongst scores, 
and the presence of multicollinearity (Sillanpaa et al., 1997). Additionally, the study was 
unclear regarding how biological measures were collected, the time frame between 
laboratory testing and the creation of the clinical index.   
Proctor et al. (2003) studied neuropsychological measures in male Danish GWVs 
(N = 215), comparing deployed (n = 143) and non-deployed veterans (n = 72). Proctor et 
al. (2003) sampled from GWV cohorts identified in a previous study (see Proctor et al., 
1998) and had participants undergo a series of neuropsychological tests (see Proctor et 
al., 2003). The sample had a mean age of 38.8 (SD = 9.7) Mood and affect were 
measured via the Profile of Mood States (POMS; McNair, Lorr, & Droppleman, 1971). 
Researchers compared groups across neuropsychological measures, controlling for age as 
the Gulf War deployed group was older than the control group. Results were not 
significant for neuropsychological domains. However, there were significant differences 




to high number of GWI-associated symptoms. Therefore, the researchers concluded that 
there was no evidence of toxin exposure leading to neurocognitive deficits. Rather, 
psychological symptoms were more likely to be reported. However, this study was 
composed of Danish soldiers who were not exposed to combat while deployed and may 
differ from other cohorts (e.g., British, American) given differential exposure to the nerve 
toxins (e.g., less endorsement of exposure to chemical warfare agents and use of anti-
nerve gas pills) and trauma.  
Consequently, these researchers concluded that complaints associated with Gulf    
War deployment were more likely psychogenic (Axelrod & Milner, 1997; Proctor et al., 
2003; Sillanpaa et al. 1997). However, psychological functioning was measured through 
differential measurements (self-report [POMS] versus objective measurements [MMPI-
2]) and did not always reflect emotional states (POMS Fatigue and Confusion). Also, 
inclusive symptoms were extensive and inconsistent with any known criteria for GWI. 
Additionally, these research studies had small sample sizes with the exception of Proctor 
et al. (2003), which may have had a sample that was limited in exposure to combat and 
chemical exposure despite deployment. Therefore, further research expanded on these 
findings by differentiating groups by GWI diagnosis.  
Gulf War Veterans – Neurotoxic Etiology Findings  
            White et al. (2001) examined central nervous system (CNS) dysfunction in GWVs 
as measured by neuropsychological tests and specific neurotoxin exposure. Participants 
(N = 240) were recruited from the Devens cohort, New Orleans cohort, and German-
deployed cohort (see Proctor et al., 1998). Veterans underwent an environmental 




Trail Making Test [TMT; Reitan, 1992], Paced Auditory Serial Addition Test [PASAT; 
Gronwall & Wrightson, 1975], WCST, Finger Tapping Test [Halstead, 1947], Purdue 
Pegboard [Purdue Research Foundation, 1948], Wechsler Memory Scale-Revised [WMS-
R; Wechsler, 1987], California Verbal Learning Test [CVLT; Delis, Kramer, Kaplan, & 
Ober, 1987], and Test of Memory Malingering [TOMM; Tombaugh, 1996]) and a 
psychological diagnostic interview. Groups were divided between those deployed to Gulf 
War combat locations (n = 193) and those stationed in Germany who did not experience 
combat and were used as a control group (n = 47). Demographic analyses revealed an 
average age of 53.8 and education level of 13.7 in the deployed group and an average age 
of 41.0 and education level of 13.7 in the non-deployed group. Both samples were 
predominately male (female percentage ranging from 12.8 to 13.1 percent) and Caucasian 
(non-white sample ranging from 0 to 16.9%). Multivariate regression analyses were used 
to control for age, education, and gender. Results comparing combat and non-combat 
GWVs on neuropsychological outcomes showed differences in mood complaints. 
Regarding neuropsychological outcomes, one measure of sustained attention (CPT) 
approached significance. However, no individual measure achieved true statistical 
significance. Of note, additional tests showed moderate effect sizes in measures of 
attention, executive, and motor functioning (PASAT, WCST, TMT-Trails A, Purdue 
Pegboard) which suggest that those deployed in the Gulf War had lower cognitive 
performance. When comparing those exposed or not exposed to toxins, significant 
differences were found in measures of tension and confusion (POMS), long-term visual 
memory (WMS-R Visual Reproduction), short-term verbal memory (CVLT), and 




on neuropsychological performance were not fully explained by mood disorders. 
Therefore, toxin exposure pointed towards specific deficits in domains of attention and 
memory. However, limitations include difficulty finding significance given the multitude 
of comparisons. 
Comparing GWI with Healthy Controls – Psychogenic Etiology Findings  
In symptomatic veterans with possible GWI (as defined by Fukuda et al., 1998), 
results using neuropsychological measures were varied (David et al., 2002). David et al. 
(2002) investigated neuropsychological patterns amongst 341 United Kingdom 
Servicemen selected from a large randomized survey (see Unwin et al., 1999). The 
sample was predominately male with a high school education; the average age was 35. 
Participants were categorized as ill or healthy based on the Physical Functioning subscale 
of the Medical Outcome Study Short-Form (SF-36; Ware & Sherbourne, 1992; Ware, 
Sherbourne, & Davies, 1988). Furthermore, participants were divided by deployment to 
the Gulf War, to Bosnia, or as an active member that did not participate in either theater. 
David et al. (2002) assessed general functioning through the WAIS-R, National Adult 
Reading Test (NART; Nelson, 1991), and Letter-Number Sequencing task of the 
Wechsler Adult Intelligence Scale-Third Edition (WAIS-III; Wechsler, 1997). Attention 
was assessed using the PASAT, Sustained Attention to Response Task (SART; Robertson 
et al., 1997), Stroop Neuropsychological Screening Test (Trenerry, Crosson, DeBoe, & 
Leber, 1989), and TMT. Memory was assessed using the WMS-R and the Camden 
Recognition Memory Tests (CRMT; Warrington, 1996). Motor skills were determined 
using the Purdue Pegboard. In addition, the veterans completed four self-report measures: 




Beck Depression Inventory (BDI; Beck & Steer, 1993), State-Trait Anger Expression 
Inventory (STAEI; Forgays, Forgays, & Spielberger, 1997), and the Mississippi Combat-
Related PTSD Scale (MCRP; Keane, Caddell, & Taylor, 1988). When investigating 
health status, the researchers found significant associations between depression and the ill 
group. Therefore, depression was controlled as a confounding factor through an 
ANCOVA. It was found that, after accounting for depression, worse performance in the 
ill group was found only in the MCRP. When comparing deployment status, there were 
no significant results once depression and multiple comparisons were controlled. 
Therefore, they concluded that there was no significant neuropsychological impairment, 
but rather, more associations with psychogenic impairment in deployed veterans which 
may better account for poor performance on neuropsychological measures. However, 
limitations include crossover effects (i.e., some participants were reassigned as ill or 
healthy between time intervals of measurements) and no differentiation between levels of 
symptomatology (David et al., 2002). 
Wallin et al. (2009) investigated neuropsychological performance in a sample 
derived from the National Health Survey of GWVs (Case group = 25, Control = 16) 
utilizing a stratified random sampling method from a pool of 700,000 veterans. The 
sample was predominately male (84%) with an average age of 34.5 and predominate 
education level of 12 years.  Wallin et al. (2009) divided groups by veterans reporting 
GWI symptomatology (using Center of Disease Control criteria) and asymptomatic 
veterans. Veterans underwent neuropsychological testing (see Wallin et al. 2009) in 
addition to psychological testing (Personality Assessment Inventory [PAI; Morey, 




for possible confounding factors. Researchers found no significance amongst 
neurocognitive testing results. However, there were differences in GWI cases in 
depression, somatic complaints, and anxiety as measured by the PAI and impairment on 
the SF-36. Therefore, researchers concluded a stronger influence of psychological factors 
over neurological factors. Several limitations were present in this study including small 
sample size (N = 41), the time between study and deployment (12 years post-deployment) 
and using self-report measures of toxin exposure.  
Therefore, both these studies (David et al., 2002; Wallin et al., 2009) further 
delineated case criteria, with results indicating more psychogenic etiology in GWI 
veterans. Although differential measures were used to investigate psychological 
measures, both studies found depression to be a significant factor and possibly distress 
associated with anxiety or trauma.  
Comparing GWI with Healthy Controls – Neurotoxic Etiology Findings  
Hom, Haley, and Kurt (1997) investigated veterans with GWI (n = 26) in 
comparison to a matched GWVs control group (n = 20) on neuropsychological and 
psychological measures. Sample had an average age of 47.81 and education level of 
11.92. Veterans with GWI were selected given their elevated scores on the six factors 
associated with GWI.  Hom et al. (1997) measured neuropsychological performance (see 
Hom et al. 1997) through an extensive battery. Psychological functioning was measured 
using the PAI, the Cornell Index (CI; Weider, Wolff, Brodman, Mitteimann, & Wechsler, 
1949), and a clinical interview. GWI veterans showed significantly worse performance 
on measures of overall neurocognitive functioning as reflected in neuropsychological 




Deficit Scale, WAIS Full-Scale IQ, Verbal IQ, and Performance IQ); therefore, they 
demonstrated lower performance as compared to controls on measures of general 
intelligence, academic abilities, executive functioning, language, visuospatial 
functioning, and sensorimotor abilities. Notable differences on specific functions were 
demonstrated in greater impairment in GWI on measures of abstract reasoning and 
problem-solving/ flexibility. These results point towards deficits in higher-level cognitive 
abilities or executive functioning. However, results showed no specific 
neuropsychological deficits or targeted brain dysfunction. Regarding psychological 
measures, GWI veterans reported more mental and physical complaints as measured by 
the PAI, similar to patterns seen in general medical patients. The researchers concluded 
that these results supported the presence of worse neuropsychological (particularly 
generalized or overall functioning) and psychological functioning in GWI veterans. 
However, these researchers hypothesized that psychological complaints were secondary 
to the physical dysfunction consistent with GWI symptoms and did not solely account for 
GWI presentation. Limitations of the study include a smaller sample size used to test 
multiple hypotheses.  
Anger et al. (1999) investigated psychological and neuropsychological differences 
via a random pool of GWVs who exhibited otherwise unexplained medical symptoms 
(i.e., cognitive/psychological changes, gastrointestinal distress, fatigue, muscle pain, joint 
pain, or skin/mucous membrane lesions). Veterans underwent a medical examination 
conducted by a physician blind to case designation. Veterans were assigned to controls if 
they did not endorse any Gulf War-related symptoms. The case sample (n=66) had a 




age of 30.6 and an education level of 13.8.  Both groups (N = 101) completed a series of 
tests assessing psychological functioning: MCRP, Penn Inventory for PTSD (PIP; 
Hammarberg, 1992), Post Traumatic Stress Disorder Checklist (PCL; Weathers, Litz, 
Herman, Huska, & Keane, 1993), SF-36, Beck Anxiety Inventory (BAI; Beck, Epstein, 
Brown, & Steer, 1988), BDI, Substance Abuse Subtle Screening Inventory (SASSI; 
Miller, 1988), SCL-90-R, MMPI-2, Positive Affect/Negative Schedule (PANS; Watson, 
Clark, & Tellegen, 1988), Life Experience Scale (LES; Sarason, Johnson, & Siegel, 
1978), and the Combat Exposure Scale (CES; Keane et al., 1989; Wolfe, Brown, Furey, 
& Levin, 1993). The neurocognitive tests implemented included Simple Reaction Time 
(Posner, 1978), Selective Attention Test (Anger et al., 1996), Digit Span (Wechsler, 
1955), Symbol Digit (Smith, 1968), Serial Digit Learning (Benton, Sivan, Hamsher, 
Varney, & Spreen, 1994), and the Oregon Dual Task Procedure (ODTP; Binder, 1993; 
Binder & Kelly, 1996; Binder & Willis, 1991). Anger et al. (1999) found statistically 
significant differences between controls and Persian Gulf cases on all thirteen measures 
of psychological functioning. However, neurocognitive results returned significance only 
for the ODTP after controlling for multiple comparisons. Using these results, researchers 
divided groups based on speed or “slow cases” and “other cases.”  Slow cases were 
identified by a score of two standard deviations above (slower) than the mean ODPT 
forced choice latency observed in the control group. The slow case subgroup (n = 13) had 
a mean ODTP latency of three standard deviations (2.7 seconds) than the control group 
mean (1.7 seconds). Consistent with performance on the ODTP, veterans in the “slow 
case” group showed slower responses than controls on Symbol Digit, Simple Reaction 




slower neurobehavioral performance on tasks of memory, attention, and response speed 
in those with GWI-related symptoms. However, results did not indicate an overall 
neurobehavioral deficit, as poorer performance was only exhibited in a subgroup of “slow 
cases” with GWI-related symptoms. Also, these results were not otherwise explained by 
psychological distress as “slow cases” data were nonsignificant with psychological 
measures. Additionally, these results were consistent with the literature investigating 
deficits in individuals with organophosphate poisoning. However, these results may not 
be generalizable as all veterans were volunteering to participate, which may indicate a 
group more motivated for treatment or with higher concerns about their health (Anger et 
al., 1999). 
Lange et al. (2001) conducted a study examining GWI and healthy veterans on 
cognitive functioning. Additionally, Lange et al. (2001) identified and accounted for the 
presence of PTSD and Major Depressive Disorder (MDD) in a group of 87 GWVs 
(healthy controls = 39; GWI = 48). Sample consisted of an average age of 34.3 and was 
predominately composed of males. Both healthy and GWI groups were administered tests 
sensitive to attention, concentration or informational processing (e.g., CPT, PASAT), 
verbal and visual memory, abstraction and conceptualization (Category Test), 
visuoperceptual and perceptual-motor functions, and fine motor functioning. A 
MANOVA found significant results in attention, concentration, and information 
processing, as well as abstraction and conceptualization. Tests reflecting attention and 
information processing (CPT and PASAT) as well as tests of abstraction and 
concentration (Category test) were significantly different (p < .05) with GWI veterans 




conducted controlling for psychopathology variables. Results indicated that GWI 
remained significant on some tests (CPT simple reaction time) but was nonsignificant 
with other tests (CPT complex reaction time, PASAT). Psychopathology was not 
correlated with performance on the CPT. Therefore, GWI was the only predictor and 
remained significant. They concluded that GWI veterans exhibited deficits on attention, 
concentration, and information processing over and above the impact of 
psychopathology. Limitations of the study include failure to investigate other etiological 
sources (i.e., toxin exposure) as well as a lack of generalizability given that the sample 
comprised of healthcare seeking veterans (Lange et al. 2001). 
The results of these studies converge in that researchers point towards cognitive 
problems associated with either GWI or a subset of GWI veterans. However, these 
studies diverge on the areas of cognitive weaknesses with one study identifying both 
global and specific decline and another identifying attention and memory decline in 
subset of a GWI-population. These studies vary in their design and have small sample 
sizes which may account for the differences in results. Of note, the diagnosis of GWI also 
remains inconsistent across modalities (i.e., factors, Fukuda et al.,1998 criteria). 
Therefore, a strength of later research is the inclusion of more reliable measures of toxin 
exposure.  
Investigating Toxin Exposure – Neurotoxic Etiology Findings  
Toomey et al. (2009) conducted a study examining GWVs (deployed and non-
deployed) on several measures of neuropsychological performance. Random sampling of 
non-deployed and deployed GWVs was utilized resulting in a sample size of 2,189 




an average age of 39; additionally, the majority of the sample had a high school education 
and were Caucasian. Veterans underwent the neuropsychological battery designed by the 
Devens Cohort study except for visual-spatial functioning tasks. Additionally, veterans 
were assessed on mental health (BDI-II, BAI, PCL) CMI complexes (i.e., similar to GWI 
diagnosis), and exposure to sarin and cyclosarin (e.g., 2000 Khamisiyah plume analyses 
and self-reported exposure). Results indicated that deployed veterans performed worse on 
a test of attention flexibility and motor speed in comparison to non-deployed veterans. 
Additional analyses showed that toxin exposure was associated with worse performance 
in verbal memory, visual memory, and psychomotor speed after controlling for 
psychological variables. However, GWI status was not associated with any notable factor 
after controlling for psychological variables. A notable limitation of the study included 
low participation rates, which may underestimate covariates such as psychiatric 
conditions (e.g., anxiety, schizophrenia, other neurocognitive disorders) as they tend to be 
less healthcare seeking compared to the research sample. However, the researchers 
sampled the participants and non-participants on depressive symptoms and did not find a 
significant difference. Therefore, researchers concluded that both toxin and psychogenic 
factors might be impacting performance, especially in different neuropsychological 
domains. 
Proctor, Heaton, Herren, and White (2006) examined the relationship between 
levels of sarin and cyclosarin exposure in GWVs and neurobehavioral functioning. As 
sarin and cyclosarin are acetylcholinesterase inhibitors, exposure leads to several CNS 
symptoms (e.g., dizziness, nausea, miosis, blurred vision, vomiting, weaknesses), 




from the Devens Cohort Study, a stratified random sample of GWVs, who completed a 
medical and history questionnaire, a semi-structured environmental interview, 
neuropsychological testing, and psychological testing (Structural Clinical Interview for 
DSM [SCID; Spitzer, Williams, Gibbon, & First, 1990], Clinical-Administered PTSD 
Scale [CAPS; Blake et al., 1995], MCRP, and Brief Symptom Interview [BSI; Derogatis, 
1993]). Sarin and cyclosarin exposure were determined through the 2000 Khamisiyah 
plume analyses or modeled exposure utilizing meteorological modeling information, 
estimates of rockets deployed, unit location and personal data, exposure thresholds, 
presence of agent removal mechanisms, and combined toxicity of sarin and cyclosarin. 
Researchers obtained plume analyses data applicable to the Devens cohort, which gave 
dosage estimates of exposure for each member. The sample consisted of mostly men with 
average age of 34.8 and education level of 13 years. Veterans were divided based on 
exposure to sarin and cyclosarin or high exposure group (> 0.072 mg min/m3 [n = 23]), 
moderate exposure group (< 0.072 mg min/m3 [n = 47]) and no exposure group (n = 70). 
Neuropsychological measures were analyzed through Student t-tests for continuous 
variables and through chi-square for categorical variables. Results indicated significant 
differences in groups on psychomotor and visuospatial abilities (e.g., Purdue Pegboard 
and Block Design) with higher exposure associated with worse outcomes, or a dose-
response with exposure (exposure matching the amount of deficit reported/observed). 
However, one limitation is the gap between exposure and outcome measurement (4-5 
years), thereby making it impossible to determine if it is a delayed or immediate effect. 
However, this study was conducted before GWI awareness was heightened amongst 




Overall, both studies were consistent in finding decreased motor speed associated 
with toxin exposure. However, more research is needed to understand deficits in 
visuospatial skills as well as the presence of psychological symptoms related to objective 
and subjective toxin exposure.  
Additional Neuropsychological Findings 
            Janulewicz et al. (2017) conducted a meta-analysis investigating the 
neuropsychological characteristics of GWI. Studies included in the analysis had GWVs 
who served from 1990 to 1991, had neuropsychological results reportable in a manner 
conducive to meta-analyses, and contained a unique sample with a total of 14 studies. 
Study results were delineated by specific domains including visuospatial abilities, 
academic achievement, attention/executive functioning, learning/memory, and motor 
skills using tests that were present in at least three studies in the meta-analysis. Also, two 
analyses were performed based on the differential samples across studies comparing 
Gulf-deployed veterans to non-deployed veterans/population norms (Group A) and Gulf-
deployed symptomatic versus Gulf-War non-symptomatic veterans (Group B). Group A 
analyses returned significance in visuospatial abilities, attention/executive functioning, 
and learning/memory, in which deployed GWVs had worse outcomes over non-deployed 
veterans. Group B studies had statistically significant differences in domains of 
visuospatial abilities, attention/executive functioning, and learning/memory, with 
symptomatic veterans exhibiting worse performance in comparison to asymptomatic 
veterans. Also, analyses indicated that Block Design, TMT-Trails A, CPT, and CVLT 
were the most sensitive in discriminating cohorts in Group A and Group B. Limitations 




sparse information reported in included studies, and the overlap between studies that 
prevented a more diverse sample. Also, data was too limited to assess toxin exposure 
concerning neuropsychological deficits. Therefore, across studies, deployed GWVs and 
symptomatic GWVs demonstrate levels of cognitive impairment, particularly in 
visuospatial abilities, attention/executive functioning, and learning/memory. 
Fatigue 
            Fatigue is the most common symptom associated with GWI (Smith et al., 2012) 
and could impact cognitive functioning. Although fatigue has not been isolated in studies 
investigating GWI, fatigue present with a known cognitive impairment has evidenced 
lowered sustained attention, concentration, processing speed, and reaction time (Fleck et 
al., 2002; Groopman, 1998). Additionally, chronic fatigue syndrome (CFS), another 
multiple chemical sensitivity syndrome, is linked to slowed processing speed (Tierskey et 
al., 1997). Michiels and Cluydts (2001) also investigated neuropsychological functioning 
in CFS and reported significantly worse processing speed, working memory, and learning 
abilities. Therefore, fatigue is noteworthy considering the prevalence of fatigue in GWI 
and its impact on cognitive functioning.   
GWI and PTSD 
Given the increased risk of trauma exposure in combat, it is not surprising that 
researchers have found a PTSD prevalence rate of 29 to 39 percent in GWVs (Al-Turkiat 
& Oheari, 2008; Labbate & Snow, 1992; Sutker, Davis, Uddo, & Ditta, 1995). However, 
prevalence rates of those with both GWI and PTSD have not been thoroughly 
investigated. Additionally, controversy surrounds the etiology of GWI, as literature 




Haley (1997) reviewed 19 articles investigating GWI and PTSD research – in this study 
he found that there were discrepancies between studies as some studies pooled samples 
from specific military units, others sampled from veteran populations by state, and others 
sampled treatment-seeking veterans. He also reanalyzed PTSD rates taking into account 
the sensitivity and specificity of the specific measures used (i.e., MCRP, SCID) and 
found a very high number of false positive cases.  Therefore, he argued that there was a 
misrepresentation of the amount of true PTSD cases present in veterans with GWI. Ford 
et al. (2001) also investigated posttraumatic stress symptomatology amongst those with 
GWI-like symptoms with a random selection of 237 GWI veterans and 113 controls. Ford 
et al. (2001) had conflicting results, as posttraumatic stress symptomatology was 
associated with GWI and to a lesser degree war zone trauma and depression. In response 
to Haley (1997), Ford et al. (2001) supported their finding in that most veterans of the 
Gulf War had lower levels of posttraumatic stress symptomatology, and therefore, did not 
meet full criteria for PTSD; additionally, they also reported that posttraumatic stress 
symptomology does not fully account for their presentation. However, Ford et al. (2001) 
argued that investigating subclinical aspects of posttraumatic stress has utility given that 
these symptoms were associated with GWI even when controlling for physical health 
symptoms, functional impairment, and life stressors. Therefore, additional research 
investigating other aspects of physical and psychological presentations such as cognition 
and immunological factors may contribute to understanding the relationship between 
posttraumatic stress symptoms and GWI. 
Vasterling, Brailey, Constans, and Sutker (1998) examined GWVs with PTSD on 




based on PTSD diagnosed via the SCID (n = 19) and compared them to healthy veterans 
with no mental disorder diagnoses (n =24). The sample was predominately male (74.4%) 
with an average age of 25.74 (SD = 9.19) and 14.26 years of education (SD = 2.02).  All 
participants underwent the Letter Cancellation task (Talland, 1965), Stroop Test, CPT, 
WCST, WAIS-R (Digit Span, Arithmetic), RAVLT, and the Continuous Visual Memory 
Test (Trahan & Larrabee, 1988). Results from the attention measures showed worse 
performance on the Arithmetic test and higher commission errors on the CPT in the 
PTSD group. The PTSD group also had worse performance on scores of the RAVLT 
measuring intrusions, recognition, and retroactive interference. Researchers hypothesized 
that the presence of cognitive intrusions (i.e., inability to inhibit thoughts or experiences 
related to trauma) could contribute to these patterns of symptoms. Using a principal 
component analysis, the researchers found that cognitive intrusions symptoms, 
particularly re-experiencing phenomenon, was related to poorer performance on memory 
and attention measures. Therefore, they hypothesized that PTSD might lead to problems 
inhibiting wrong answers and filtering information unrelated to the task at hand. 
Additionally, the researchers found that PTSD-diagnosed veterans had difficulty on 
measures of sustained attention and mental manipulation over other measures of attention 
(i.e., selective attention). Of note, the study was limited given that the study had a small 
sample and their case sample also had co-morbid diagnoses outside of PTSD. 
Researchers also were unable to compare results with differential clinical samples with 
mental diagnosis outside of PTSD to differentiate the impact of trauma related stress over 
general emotional distress. Finally, the researchers noted that cognitive changes may be 




threats) which was not used as a manipulation in this study (Vasterling et al., 1998). 
Lindem et al. (2003) investigated neuropsychological performance in conjunction 
with self-reported chemical exposure and severity of trauma symptoms with a sample of 
225 participants (Devens cohort = 141, New Orleans cohort = 37, Germany cohort = 47) 
comprised of those deployed and non-deployed during the Persian Gulf War. The 
Germany cohort was used as a comparison group as this cohort was exposed to the 
military-related stress; however, they did not experience the same combat or 
environmental exposure as their counterparts stationed in the Gulf War. The sample of 
participants deployed to the Gulf War (n = 178) had a mean age of 34.9 (SD = 9), a mean 
education of 13.9 (SD = 2.1), were roughly equivalent in gender (male = 55.9%, female = 
44.1%), and predominantly Caucasian (82.2%). The sample of non-deployed veterans 
had a mean age of 41.0 (SD = 9.1), a mean education of 13.7 years (SD 1.5), were 
predominantly male (87.2) and Caucasian (100%). Participants were administered the 
CAPS to determine the level of trauma symptoms and combat exposure was assessed 
using the CES (Keane et al., 1989; Wolfe et al., 1993) with additional items relevant to 
the Gulf War (i.e., chemical exposure). Health symptoms were measured with the 
Expanded Health Symptom Checklist (HSC: Bartone, Ursano, Wright, & Ingraham, 
1989). Regarding neuropsychological testing, the veterans underwent tests of general 
intelligence (i.e., WAIS-R Information), attention and executive functioning (WAIS-R 
Digit Span, WMS-R Digit Span, CPT, TMT, WCST, PASAT), motor functioning (Finger 
Tapping Test, Purdue Pegboard), visuospatial constructional abilities (WAIS-R Block 
Design), verbal memory (WMS-R Verbal Paired Associates, CVLT), visual memory 




exposure was assessed through self-report measure and a clinical interview. Partial 
correlational analyses including all veteran groups found a significance between severity 
of PTSD symptoms reported and performance in attention, executive functioning, motor 
functioning, memory, and mood subscales while controlling for age, education, WAIS-R 
Information score, deployment status, depression, and disability. Partial correlational 
analyses for Gulf War deployed veterans revealed that severity of PTSD symptoms was 
significantly correlated with general intellectual ability, sustained attention, motor speed, 
motor coordination, verbal learning, and mood while controlling for age, education, and 
WAIS-R Information. The same analysis was conducted for Germany deployed veterans, 
and there were significant findings in measures of simple attention, sustained attention, 
and some mood scales. For Gulf War deployed veterans that reported chemical exposure 
(n = 30), partial correlation analyses showed worse performance in sustained attention, 
motor speed, and motor coordination even after controlling for age, education, WAIS-R 
Information, depression, and disability. Additionally, the same analysis was used to 
investigate PTSD severity and neuropsychological performance in GWVs that denied 
chemical or biological warfare (CBW) exposure. Results indicated a significant 
relationship in measures of cognitive tracking, motor speed, motor coordination, and 
mood.  
To further investigate the relationship between PTSD severity and CBW 
exposure, regression analyses were performed to investigate how PTSD severity and 
CBW exposure predicted neuropsychological performance while controlling for age, 
education, and WAIS-R Information. Researchers found that PTSD was associated with 




learning, visual memory recognition, and mood. CBW exposure was associated with 
worse performance on sustained attention, verbal memory, visual memory delayed recall, 
and mood. Researchers concluded that the severity of PTSD contributed to declines in 
short-term verbal memory (acquisition, retrieval, semantic clustering). Additionally, 
severity of PTSD suggested difficulties with sustained attention, motor functioning, and 
intellectual functioning. In regard to CBW exposure, researchers concluded that severity 
of PTSD was associated with specific tasks of sustained attention, number of 
perseverative responses in verbal memory tasks, visual memory, and mood measures. 
Limitations of this examination include the use of cross-sectional analyses over a 
longitudinal design as it is difficult to determine what neurocognitive weaknesses were 
present prior to deployment. Additionally, the analyses were dependent on subjective 
measures of exposure to chemicals over more objective measures (Lindem et al., 2003).   
Sullivan et al. (2003) also investigated neuropsychological performance in GWVs 
with PTSD concerning PB exposure, a chemical linked to neurotoxic effects. Sullivan et 
al. (2003) used a sample of 260 veterans which were divided into a group that was 
deployed and seeking treatment (i.e., for cognitive or health symptoms) and a control 
group (i.e., non-deployed GWVs who were not seeking treatment). Researchers 
determined toxin exposure through the use of military records and self-report exposure 
questionnaires. All veterans underwent a neuropsychological battery (see reference for 
full battery list) in addition to a CAPS to determine PTSD status. In comparison to non-
deployed veterans, deployed veterans had worse performance in measures of attention 
(WAIS-R Digit Span), visuospatial skills (WAIS-R Block Design), and visual memory 




Veterans exposed to PB showed worse performance on the WCST. However, there was 
no difference between those with and without PTSD on neuropsychological measures. 
Therefore, the researchers concluded that deployment and PB exposure led to some 
notable deficits.  
Sullivan et al. (2018) investigated how differing levels of pesticide exposure and 
PB intake contributed to neuropsychological dysfunction. The researchers recruited 
veterans with functional knowledge of their exposure to these toxins as they held roles as 
preventative medical personnel. The sample (n = 159) had an average age of 48, an 
average education level of 16 years, and were predominately male (87%). Researchers 
also used Department of Defense environmental exposure reports to divide participants 
into four groups: group one (i.e., low pesticide, low PB), group two (i.e., high pesticide, 
low PB), group three (i.e., low pesticide, high PB), and group four (i.e., high pesticide, 
high PB). All veterans completed several neuropsychological tests. Noteworthy tests 
include the CPT, CVLT-II, TMT, WCST, Rey-Osterrieth Complex Figure Test (ROCF; 
Taylor, 1959), Grooved Pegboard, and Finger Tapping Test. Veterans were also assessed 
for psychological functioning via the POMS and CAPS. GWI was screened for using 
CMI criteria (Fukuda et al., 1998). The data were analyzed with a series of multivariate 
and univariate analyses. Univariate analyses of covariance demonstrated that high 
pesticide/high PB exposure was associated with worse CPT and on the POMS sub scores. 
These analyses remained significant with PTSD as a covariate, demonstrating a main 
effect on attention reaction time in comparison to the low pesticide/low PB group. 
Additionally, high pesticide exposure/low PB exposure was significantly worse on a 




low pesticide/low PB group. Multivariate analyses were performed with a MANCOVA 
using a summary score for all cognitive tests as the dependent variables and all four 
participant groups as the independent variable. Significant differences were found in 
psychomotor, mood, attention, and memory domains when considering demographic 
covariates (i.e., age, education, gender). However, psychomotor, attention, and memory 
domains only remained significant when CMI was added as a covariate when considering 
the model as a whole. Researchers found that a higher rate of CMI was associated with 
the high pesticide/high PB group which evidenced worse cognitive performance in 
attention, motor, and memory domains. These results are consistent with problems in 
short-term memory, attention, and processing speed in a research investigation of 
organophosphate exposure amongst pesticide, greenhouse, and livestock employees. 
Overall, results showed that high pesticide/high PB exposure had worse performance on 
information processing reaction times, attentional errors and visual memory accompanied 
by increased mood complaints. Limitations of this study include the multitude of analysis 
with a smaller sample size, increasing the chance of finding significance. Additionally, it 
is possible that, although the sample had a sophisticated knowledge of their exposure, 
their exposures were correlated (i.e., exposure to PB associated with exposure to 
vaccines, nerve agents, and pesticides). Additionally, pesticide and PB classifications 
were reliant on self-report exposure 
Considering the research on GWVs in regard to PTSD and chemical exposure, 
there is some consistency in that chemical exposure, per self-report, may negatively 
impact attention, visual memory, and mood. However, patterns are not necessarily clear 




attentional errors). It also remains unclear if there is a pattern specific to the type and 
variety of exposure. Finally, the Sullivan et al. (2018) study was the only one that 
considered GWI or CMI as a covariate, limiting the ability to see a trend related to 
neuropsychological performance and GWI. Future research would benefit from using 
specific criteria to examine GWI and more objective measures of immunological 
dysfunction to elucidate neurocognitive performances in GWI with PTSD.  
GWI Biomarkers, Trauma, and Neuropsychological Performance 
            As GWI has been linked to an underlying immunological process via toxin 
exposure, additional studies associating psychological and neuropsychological 
functioning in conjunction with immunological performance could further elucidate 
contributions of cognitive decline. Currently, only one published study has investigated 
immunological biomarkers (i.e., cytokines, genetic expression data, cortisol) in 
conjunction with trauma, fatigue, and neuropsychological performance (Broderick et al., 
2013). In this study biomarkers were examined under an exercise challenge to prompt 
immunological response mechanisms in a sample of GWI participants (n = 20) CFS 
participants (n = 7) and healthy veteran controls (n =22). All participants were male and 
comparable in age (range of 30 to 55), body mass index, ethnicity, and duration of illness. 
Participants were administered a variety of measures notably the Davidson Trauma Scale 
(DTS; Davidson et al., 1997), the Multidimensional Fatigue Inventory (MFI; Smets, 
Garssen, Bonke, & De Haes, 1995) and the PASAT. Immune response was activated with 
a standard exercise test using the McArdle protocol (see McArdle et al., 2007). Blood 
was collected at three time points during the exercise challenge (i.e., prior to exercise 




Sixteen different cytokines were analyzed via blood plasma with a quantitative enzyme-
linked immunosorbents assay (ELISA)-based test. Using partial correlation analyses, 
Broderick et al. (2013) analyzed cytokine correlates with measure results during rest, at 
peak effort, and during recovery. Results indicates that lower interleukin-10 (IL-10) 
levels at peak effort was significantly associated with scores on the DTS and lower scores 
on the PASAT. Results concerning the MFI was more varied and was associated with 
changes in interleukin 4 (IL-4), interleukin 12 (IL-12), and IL-10. However, this study 
was also limited in that a small sample was used to conduct a multitude of analyses.  
            Barker et al. (2015) also conducted a pilot analysis for a poster presentation 
investigating the biobehavioral differences in GWI participants with and without self-
reported trauma. Using the data collected through the exercise challenge study (see 
Broderick et al., 2013 for details), researchers divided the participants (N = 21) into two 
groups via K-means clustering based on DTS scores. Additionally, researchers examined 
how these two groups differed on self-reported health outcome measures (SF-36, MFI) 
immune cytokine profiles, and autonomic variables (heart rate variability, work 
percentage predicted) with an ANOVA analysis. Results indicated that the group with 
higher DTS scores significantly differed (p <.0.01) from the lower DTS group in terms of 
age and SF-36 Social Functioning. Therefore, these results indicated that higher DTS 
scores were associated with older veterans with self-reported problems with social 
functioning. Additionally, the group with higher DTS scores showed significant 
differences (p < 0.05) reflecting diminished functioning as a result of health-related 
issues (SF-36 Vitality, SF-36 Physical Functioning), higher fatigue levels (MFI General 




cardiac output (work percentage predicted). Of note, some measure results approached 
significance (p < 0.06) indicating that those with higher DTS scores had higher IL-4 
concentrations at peak exercise and four hours post-exercise, higher heart rate variability, 
and poorer emotional role functioning (SF-36 Emotional Role Functioning). However, 
considering the small sample size, the p-value had limited value given that the study was 
underpowered. Considering these results, the researchers hypothesized that veterans with 
trauma-based symptoms may have higher levels of IL-4 at peak exercise and four hours 
post exercise. However, more research is necessary to understand if IL-4 was elevated 
based on trauma over age-related IL-4 elevations.  
            Although the literature is not abundant, these two studies are indicative of a 
possible immunological process that may be contributing to problematic psychological 
patterns (i.e., poor social and emotional functioning, low motivation), fatigue, and worse 
attention processes (i.e., PASAT). Therefore, further research investigating interleukin as 
a biomarker in conjunction with psychological and cognitive measures may elucidate 
more patterns to understand the unique contributions of biological versus psychological 
factors in GWI presentation.  
Summary of the Literature  
            GWI is chronic, multi symptom illness, impacting the health of a significant 
amount of GWVs; however, the etiology and treatment of GWVs remains somewhat 
elusive, prompting the demand for more research. Research investigating the 
neuropsychological underpinnings of GWI is especially needed given the prevalence of 
cognitive symptoms in GWVs, possibly the second most reported symptom in GWI 




            Early studies of neuropsychological functioning and GWVs focused more on the 
etiology of these symptoms with conflicting results pointing either towards a psychogenic 
or neurological cause. These studies did not use an established criterion and compared 
groups based on their deployment status (deployed, non-deployed) and/or symptom 
presence (reporting symptoms, not reporting symptoms). Some researchers found that 
their group of interest (deployed or symptom reporting) endorsed higher psychological 
distress (Axelrod & Milner, 1997; Proctor et al., 2003; Sillanppa et al., 1997). However, 
this research did not necessarily clarify neuropsychological performance in GWI as it is 
understood in current literature, as symptoms were not classified into a specific diagnosis. 
Additionally, other studies that controlled for trauma (Proctor et al., 2003) did not utilize 
a sample that was exposed to combat, and therefore, may not reflect the same etiology as 
those exposed to combat and chemical exposure.  One researcher comparing GWVs 
(White et al., 2001) found evidence of a neurotoxin impact in GWVs leading to worse 
neuro-cognitive performance. However, there was still evidence of higher psychological 
distress in addition to poorer performance specifically in attention and memory tests. 
Therefore, these conflicting findings prompted further research that delineated GWI 
through more testable operational definitions.  
Despite the efforts to establish criteria for GWI, researchers continued to find 
mixed results on the etiology of GWI centering on the debate of a psychogenic or 
neurotoxic underpinning. David et al. (2002) found substantial evidence of psychogenic 
nature of GWI using the Fukuda et al. (1998) criteria. With the use of an extensive mood 
and neuropsychological batteries, they found depression confounded the results between 




findings and only found differences in GWI on depression, somatic complaints, and 
anxiety. However, additional research (Hom et al., 1997) also eluded to more 
physiological causes. Earlier research showed more impairment in general scores of 
neuropsychology tests (i.e., Halstead-Reitan Index, Weschler Indexes), which made it 
difficult to ascertain the different neurological areas and pathways that were impaired. In 
addition, researchers (Anger et al., 1999) investigated different levels of symptoms 
related to the Gulf War comparing those with slower reaction times to those who were 
not impaired on processing speed. Those GWVs with slower times also had memory 
impairment, pointing towards difficulty with basic processing and encoding skills. 
Nevertheless, focusing on criteria or the presence of Persian-related symptoms did not 
necessarily clarify the etiology of GWI. Differences in findings could account for 
different samples as well as differing measures for neuropsychological and psychological 
functioning.  
Of note, these studies did not specifically address the level of neurotoxicity 
exposure, as differing levels of toxins can have a mild to severe impact on physiological 
functioning. Additional research was conducted comparing groups based on 
sarin/cyclosarin exposure via self-report and found reported higher exposure to 
sarin/cyclosarin was associated with lower performance in a visuospatial and motor 
functioning task. Further research partially supported this finding as toxin exposure was 
associated with reduced motor speed. However, toxin exposure also impacted scores 
reflecting poor attentional flexibility. Therefore, based on the different methods (i.e., 
sampling, operational definition of toxin) and differing neuropsychological measures 




more research is needed before definitive conclusions can be made.  
To address these conflicting findings, Janulewicz et al. (2017) conducted a meta-
analysis from GWI neuropsychological research. They compared data from deployed and 
non-deployed veterans as well as deployed veterans that were symptomatic and 
asymptomatic. When comparing deployed and non-deployed veterans, they found worse 
performance in deployed veterans in visuospatial abilities, attention/ executive 
functioning and learning/memory. When comparing asymptomatic and symptomatic 
veterans, symptomatic veterans had similar results, supporting the idea that symptomatic 
veterans present with neuropsychological deficits.   
Lastly, as PTSD has a high prevalence rate in GWVs, this review also included 
research investigating PTSD and GWVs in relation to neuropsychological performance. 
Vasterling et al. (1998) divided GWVs based on the presence or absence of PTSD and 
found worse performance in the PTSD group on measures of different components of 
memory (i.e., working memory, intrusions, recognition, and interference) and attention. 
They found that these memory and attention issues were possibly related to the presence 
of cognitive intrusions, particularly in the re-experience of trauma (Vasterling et al., 
1998). Lindem et al. (2003) also investigated PTSD in relation to cognitive performance 
and chemical exposure. They found that GWVs with PTSD had worse performance on 
general intellectual ability, sustained attention, motor speed, verbal learning, and mood 
measures. Sullivan et al. (2003) investigated PTSD and the deployment status of veterans 
on neurocognitive performance, finding that deployed veterans with PTSD more likely 
had problems with attention, visuospatial skills, and visual memory as well as higher 




neurocognitive impairment, especially in regard to memory and attention.  
Although research is varied on GWI, there remains preliminary evidence of 
possible neuropsychological deficits. The etiology of these results remains unclear as 
both emotional and true neurological damage have been identified as causes. Given the 
complexity of retrospective analyses, it may be a combination of psychological and 
biological factors. However, research has improved to support evidence of GWI leading 
to neurological deficits measurable through neuropsychological batteries, particularly in 
areas including attention, memory, motor functioning, and executive functioning. Notable 
improvements include the use of established criteria and measuring toxin exposure. 
However, future research would benefit from continuing to use established criteria when 
investigating neuropsychological performance in GWI. GWI research would also benefit 
from including self-report and modeled measures of toxin exposure. However, increased 
use of bio marker research may also be a helpful introduction to GWI neuropsychological 
research. For instance, research on cytokine profiles of GWI have shown immunological 
homeostatic shifts, which lends credence to a neurological etiology in GWI (Craddock et 
al., 2015). Finally, there has been a lack of research investigating GWI and PTSD 
together in conjunction with neuropsychological results. Therefore, it is difficult to 
understand how these two diagnoses create neuropsychological profiles, given that they 
both lead to poorer performance on neuropsychological measures. This lack of research is 
especially problematic for practicing neuropsychologists given the high prevalence of 
PTSD in their patient population as well as the possibility of encountering a patient who 
has GWI. 




functioning (i.e., cytokines), psychological status, and GWI indicate that differential 
levels of cytokines in GWI veterans may be related to problematic psychological patterns 
(i.e., poor social and emotional functioning, low motivation), fatigue, and worse attention 
processes (i.e., PASAT). Therefore, these studies support the utility of investigating 
biological markers alongside psychological measures to better understand the biological 
and psychological contributions to GWI presentation as demonstrated in a test of 
attention and working memory.  
Purpose 
            The purpose of the present dissertation project was to investigate how veterans 
diagnosed with GWI perform on measures of cognition, while considering their level of 
fatigue and PTSD symptoms. Both GWI and PTSD-related symptoms have been 
associated with neuropsychological decline. However, it remains unclear how GWI and 
PTSD symptoms uniquely contribute to cognitive decline. It is also difficult to accurately 
measure neurocognitive performance in GWI given that GWI often presents with fatigue. 
Fatigue leads to lower performance in cognitive measures (Tierskey et al., 1997), and can 
be misattributed to neurologically mediated deficits.  
            The present study also incorporated measures of immunological performance and 
its impact on fatigue levels. Specifically, we investigated the unique contributions of IL-4 
and IL-10 levels on measures of reported fatigue. The same measures of fatigue were 
included in the neuropsychological analyses, to link fatigue as expressed by 
immunological processes in GWI to neuropsychological performance.  
            Therefore, this study is an examination of the influence of GWI, PTSD-related 




working memory (i.e., PASAT). Additionally, this study investigated fatigue and its 
association with interleukin levels to further understand immunological processes of 
























Chapter III: Methods 
            All study materials and procedures were approved by the Institutional Review 
Board (IRB) of the University of Miami. Ethics review and approval for data analysis 
was also obtained via the IRB of the University of Alberta. Given the de-identified nature 
of the data received by the investigator, separate IRB approval via the Nova Southeastern 
University was not necessary. Recruitment occurred between April 2006 and May 2008 
through the Miami Veterans Administration Medical Centers, clinics, and the local 
veteran community.  
Participants  
Participants were selected from a de-identified, archival database gathered 
through the Gulf War Illness Consortium based in Florida. Inclusion criteria mandates 
participants must have served between August 1990 and July 1991. Those with a history 
of a prior central nervous system or psychiatric diagnosis that would significantly impact 
cognitive functions (i.e., stroke, epilepsy, Alzheimer’s Dementia, schizophrenia) were 
excluded. Veterans were placed in the GWI group if they met criteria for case definition 
(Fukuda et al., 1998). Case definition was defined as moderate to severe symptoms 
persisting for six months or longer in at least three of the following domains: respiratory, 
gastrointestinal, neuropsychological, sleep disturbances, and pain (Steele, 2000). All 
other veterans were placed in the control group if they had no exclusionary diagnoses. 
Veterans in the control group were matched by age, ethnicity, and BMI to GWI 
counterparts. 
Data for the study was derived from an original sample of 99 male veteran 




data for the desired analyses. We excluded veterans with higher PTSD symptoms from 
the healthy group (n = 8) to ensure a valid healthy control group. As such, sixty-two male 
participants, with an age range of 30 to 58, comprised the complete data including the 
PASAT, MFI, DTS, and cytokines of interest. However, some measures had missing 
data, which impacted the utilized sample population as analyses were conducted listwise. 
Measures  
            Paced Auditory Serial Addition Test (PASAT). The PASAT is a test of 
working memory, divided attention and information processing speed appropriate for 
those aged 16 to 74. The examinee played a tape recording with a random array of 
numbers ranging from 1 to 9. The participant was instructed to consecutively add pairs of 
numbers so that each number is added to the number spoken previously. The participant 
undergoes four trials in total with each trial incrementally increasing the speed of the 
numbers, thereby decreasing the time allotted for the participant to process the 
information and respond. The trial speed between number exposure is 2.4 seconds for the 
first trial, 2.0 seconds for the second trial, 1.6 seconds for the third trial, and 1.2 seconds 
for the last trial (Gronwall, 1977). Regarding reliability, the PASAT has evidenced high 
internal consistently (Cronbach’s alpha = .90; Crawford, Obansawini, & Allan, 1998) and 
test-retest reliability over three months (r = .83-.96; Sjogren, Thomsen, & Olsen, 2000). 
In terms of validity, the PASAT has also demonstrated adequate convergent validity 
compared to other measures of attention including the Auditory Consonant Trigrams, d2 
Test, TMT, Visual Search and Attention Test, and Stroop test (Gronwall & Wrightson, 
1981; Sherman, Strauss, & Spellacy, 1997). Additionally, the PASAT has shown 




1991; Schachinger, Cox, Linder, Brody, & Keller, 2003). In terms of construct validity, a 
factor analysis has shown that PASAT loads onto a three-factor model of attention, 
immediate memory, and information processing (Larrabee & Curtiss, 1995). Cronbach’s 
alpha for the all trials of the PASAT for this sample was .923, which demonstrates a high 
level of consistency for this analysis.  
            Multidimensional Fatigue Inventory (MFI). The MFI is a 20 item self-report 
measure designed to assess fatigue within five subscales: General Fatigue, Physical 
Fatigue, Mental Fatigue, Reduced Motivation, and Reduced Activity. Higher scores on 
the measure reflect higher levels of acute fatigue. The MFI has adequate internal 
consistency with a Cronbach’s alpha of .84. Additionally, the MFI showed construct 
validity as the five-factor model of fatigue was supported by confirmatory factor analysis. 
Finally, convergent validity was somewhat supported (0.22 < r < 0.78) when compared to 
the Visual Analogue Scale measuring fatigue (Smets et al., 1995). Cronbach’s alpha for 
this sample (.95) also showed a high level of internal consistency.  
            Davidson Trauma Scale (DTS). The DTS is a self-rated measure of PTSD 
criteria and further delineates the severity and frequency of these symptoms. The use of 
this measure is supported by sufficient test-retest reliability (r = 0.86) and internal 
consistency (r = 0.99) as well as good convergent and divergent validity with the SCID 
(Davidson et al., 1997). Additionally, researchers found that a cutoff score within the 
range of 68-72 provided optimal diagnostic accuracy given that the sample matched the 
veteran prevalence rate (12-13%) and accurately classified 90% of the cases with PTSD 
(McDonald, Thompson, Stratton, & Calhoun, 2014). However, even though this score is 




study, the DTS was used as a measure of the level of PTSD symptoms to investigate 
PTSD symptoms as a spectrum rather than use it as a screening measure to assign a 
diagnosis without an accompanying clinical interview.  
Procedures  
            Participants were given a full explanation of the requirements, benefits, and costs 
of the study. If the participant understood these parameters, the study investigator or IRB-
approved delegate obtained informed consent. The participant was also reminded of the 
aspects of the study and his rights as a participant. After consent was obtained, 
participants received a physical examination and a medical history was gathered - 
including a GWI symptom checklist. Following the examination, the veteran completed 
pertinent questionnaires including the MFI and the DTS. Next, all veterans were assessed 
using the PASAT. Immune response was stimulated through a standardized exercise 
challenge test (see Broderick et al., 2013 for details). Blood was drawn prior to exercise, 
at peak effort as measured by VO2 max, and four hours post-exercise. In addition, MFI 
was measured prior to exercise, at peak exercise, and four hours post-exercise. For each 
blood sample, plasma was separated within two hours of collection and stored at -80 
degrees Celsius until processing. A total of 16 cytokines (including IL-10 and IL-4) were 
analyzed with Quansys reagents and instruments. These cytokines were identified 
through a quantitative ELISA plate or through distinct patterns of antibodies in a 96-well 
plate array. To compare between subject groups, data was adjusted previously to account 
for the range of the standard curve and exposure time for reliable comparisons at both 





After collecting data, each case was assigned a specific code number to ensure 
that no personal identifying information was contained in research materials. An 
electronic code, which matched materials linked to personal health information, was used 
only for patient tracking/safety purposes and password protected. All data were kept in 
locked file cabinets accessible only to authorized staff. Data are coded without any 
personal health information.  
Hypotheses 
            The present study had two overarching hypotheses, with sub-hypothesis within 
each major question. First, it was hypothesized that 1a) a GWI diagnosis, higher levels of 
PTSD symptoms, and higher fatigue symptoms would lead to poorer performance on a 
survey measure of attention and working memory (PASAT). Additionally, it was 
predicted that 1b) GWI diagnosis would be the most important factor leading to worse 
testing performance over and above demographic factors, severity of PTSD, and severity 
of fatigue. Next, it was hypothesized that 1c) PTSD symptom severity would be the 
second most important factor leading to poorer performance on measures of attention and 
working memory. 
            The second overarching hypothesis was that 2a) the presence of GWI and 
elevated levels of IL-10 and/or IL-4 would lead to higher endorsement of fatigue in the 
MFI including Physical Fatigue, Mental Fatigue, Reduced Activity, Reduced Motivation 







Chapter IV: Results 
Overview  
            The hierarchical regression analyses were conducted through multiple steps. First, 
education was recoded via dummy coding with elementary school used as the baseline. 
The first analyses was designed to measure how GWI status, PTSD symptoms, and 
fatigue, would impact scores on the PASAT. Age and education were the first variables 
in the model (Block 1) to account for confounding sources of variance. Second, the 
categorical variable of condition as defined by either healthy control or GWI was entered 
(Block 2). The next block included the PTSD symptoms variable as measured by the 
DTS (Block 3). Finally, fatigue, as measured by the overall score of the MFI (General 
Fatigue), was included in the final Block (Block 4). These analyses were applied to all 
four trials of the PASAT. 
            The next analysis was designed to measure how health condition (i.e., GWI or 
healthy control), then cytokine variables (i.e., IL-10 and IL-4) impacted how veterans 
reported their fatigue on the MFI. Condition was added as the first variable (Block 1). 
The next block (Block 2) consisted of interleukin IL-10 and IL-4 levels. These analyses 
were applied to all sub scores of the MFI including Physical Fatigue, Mental Fatigue, 
Reduced Activity, Reduced Motivation, and General Fatigue.   
            For all analyses, the alpha level was set to .05. Additionally, given the smaller 
sample sizes (and the inverse association between sample size and statistical significance 
levels), effect sizes were also reported to provide meaningful information about the 
magnitude of effects. The effect sizes for full models of regression were based on the R2 





2). The values (Cohen, 1988) were interpreted with following cutoffs: > 
.02  (small) , > .13 (medium) , and  > .26 (large).  
Descriptive Characteristics  
            The sample included only male participants who were veterans of the Gulf War. 
The sample was predominately Caucasian (n = 44; 72.1%), with one participant who 
identified as Asian and 16 participants who identified as African American. A sample 
consisted of a relatively equivalent amount of non- Hispanic/Latino participants (n = 33), 
and Hispanic/Latino participants (n = 28). Age grouping revealed 20 participants were 
between the ages 30 to 39 (32.3%), 34 participants were between the ages 40 to 49 
(54.8%), and eight participants were between 50 and 58 (12.9%). Education level also 
varied, as 1 participant completed elementary school (1.7%), 24 participants had a high 
school diploma (40.7%), 26 participants had a four-year college degree (44.1%), and 8 
participants had a doctoral degree (12.9%). See Table 1 for more details on participant 
characteristics between health conditions.  
Table 1 
Demographic Characteristics Between Health Conditions  
Characteristic GWI Healthy Controls 
 (n = 31) (n = 31) 
 n % of group n % of group 
Age     
30-39 10 32.26 10 32.26 
40-49 18 58.06 16 51.61 
50-58 3 9.68 5 16.13 
Race*     
White 21 67.74 23 76.67 
Asian  1 3.23 0 0 
African American  9 29.03 7 23.33 
Ethnicity*      
Hispanic/Latino(a) 13 41.94 15 50 
Not Hispanic/Latino(a) 18 58.06 15 50 
Education*     
Elementary School 1 3.23 0 0 
High School 12 38.71 12 40 
College  14 45.16 14 46.67 
Doctorate  4 12.90 4 13.33 




            Additionally, analyses between the GWI and control group produced means on all 
key measures including the DTS, MFI, and PASAT (see Table 2). Of note, the 
investigator reported on all sub scores of the DTS to demonstrate where both groups fell 
on particular PTSD symptom clusters (i.e., intrusive symptoms, avoidance, and 
hypervigilance). However, only the total DTS score was utilized in the overall 
hierarchical analyses of interest.  
Table 2 
Key Measure Means Between Health Conditions   
Measure GWI Healthy Controls 
 (n = 31) (n = 31) 
 Mean SD Mean SD 
DTS*     
Intrusion  23.06 10.88 3.35 7.20 
Avoidance 29.58 16.88 2.84 6.82 
Hypervigilance 26.39 10.13 3.94 8.79 
Total 79.03 35.18 10.13 20.61 
MFI     
Physical Fatigue  60.14 24.41 13.33 15.64 
Mental Fatigue  65.86 27.69 15.00 21.15 
Reduced Activity 53.88 25.00 16.40 16.28 
Reduced Motivation 52.82 26.69 13.33 13.33 
General Fatigue 65.42 22.56 17.88 16.81 
PASAT     
Trial 1 35.86 12.21 38.28 13.69 
Trial 2 33.18 10.16 37.17 12.05 
Trial 3 28.50 10.16 32.55 9.39 
Trial 4 21.14 10.20 25.17 7.84 
Note: *DTS scores in the healthy control group are likely lower in means given the exclusion of veterans   
(n = 8) with high PTSD levels (DTS score >70) to ensure a healthy control group 
 
            Differences between the GWI and control group on demographic variables were 
analyzed using a one-way ANOVA. Age was not statistically significant when comparing 
the control group (M = 43, SD = 6.53) and the GWI group (M = 43, SD = 6.53), F(1, 60) 
= .132, p = .717, η2 = .002. Education was not statistically significant when considering 
the control group and the GWI group for the following educational levels: high school, 




doctorate, F(1, 57) = .023, p = .880, η2 = > .001. A chi-square test was used to test if 
groups differed by race X2 (1, N = 62) = .576, p = .78 and by ethnicity X2 (1, N = 62) = 
.527, p = .61. There were no statistically significant differences seen between individuals 
with GWI and healthy controls.  
PASAT Results by Condition, PTSD Symptoms, and Fatigue  
In the first set of hierarchical regression models, the four trials of the PASAT 
were analyzed in separate models. Predictor blocks were held constant across models: 
Block 1 (Age, Education), Block 2 (GWI or Healthy Control), Block 3 (PTSD 
symptoms), Block 4 (Fatigue symptoms) with the full model consisting of all blocks. 
Tables 3 through 9 present selected statistical information from the analyses.  
PASAT Trial 1. Regression models were used on available data (n = 48). The 
full model for PASAT Trial 1 was nonsignificant, R2 = .189, 95% CI [.028, .350], F(7, 
40) = 1.330, p = .262, adjusted R2 = .047. The first predictor block – including age and 
education – was nonsignificant, R2 = .178, F(4, 43) = 2.324, p = .072, adjusted R2 = .101; 
however, it demonstrated a medium effect. The addition of health condition on the 
second predictor block did not account for significant incremental variance in Trial 1, 
∆F(1, 42) = .146, p = .704,  ∆R2 = .003. The addition of PTSD in the third block also did 
not provide significant incremental variance in Trial 1, ∆F (1, 42) = .259, p = .614,  ∆R2 = 
.005. Finally, the addition of the last block, fatigue level, failed to produce significant 
incremental variance, ∆F (1, 40) = .152, p = .699,  ∆R2 = .003. In the final model, age was 
associated with lower scores (rsp
 = -.208, 95% CI [-.465, .081]) with a small effect (rsp
2 = 
0.04). Education at the high school level (rsp
 = .164, 95% CI [-.126, .428]; rsp
2 = 0.03), 
college level (rsp
 = .136, 95% CI [-.154, .405]; rsp





.216, 95% CI [-.073, .471]; rsp
2 =0.05) were positively associated with the PASAT with 
small effect. Health condition (rsp
 = .044, 95% CI [-.243, .324]; rsp
2 = 0.00), PTSD 
symptoms (rsp
 = -0.04, 95% CI [-.320, .247]; rsp
2 = 0.00), and fatigue symptoms (rsp
 =        
-0.06, 95% CI [-.338, .228]; rsp
2 =0.00) did not show a statistical or meaningful 
association. 
Table 3 
PASAT Trial 1 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2 B rsp2 B rsp2 B  rsp2 
Constant 50.230  52.714  48.370  47.916  
Age -.643 .07 -.665 .07 -.583 .04 -.573 .04 
Edu. Level         
 High School  15.367 .03 14.265 .02 15.794 .03 16.459 .03 
 Collegiate 12.039 .02 11.202 .01 12.305 .02 13.194 .02 
 Doctoral 21.040 .05 20.126 .04 21.070 .04 21.733 .05 
Condition a   -1.458 .00 .941 .00 2.110 .00 
PTSD Level b     -.037 .01 -.022 .00 
Fatigue c       -.047 .00 
         
R2 .178  .181  .186  .189  
R2 adj .101  .083  .067  .047  
F 2.324  1.851  1.559  1.330  
Δ R2 .178  .003  .005  .003  
Δ F 2.314  .146  .259  .152  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total), c Fatigue (as designated by MFI General Fatigue); B indicates unstandardized 
coefficient, rsp2 indicates a semi-partial correlation squared 
 
PASAT Trial 1 Reanalysis without Outliers. Assumption testing of the data 
revealed two potential outliers which were excluded for the following analysis (n = 46). 
The analysis interpretation did not change as the full model for PASAT 1 remaining 
nonsignificant (see Table 4 for comparison values). There was no notable change in ∆R2, 
as it did not produce significant or meaningful results. Regarding semi-partial 
correlations, age (rsp
 = -.254, 95% CI [-.507, .039]; rsp
2 =0.06) continued to have a small 
negative impact on PASAT scores as stipulated in the previous analysis.  Education at the 
high school level (rsp
 = .165, 95% CI [-.132, .434]; rsp
2 =0.02) and the doctoral level (rsp
 = 
.217, 95% CI [-.078, .477]; rsp




association with the PASAT. 
PASAT Trial 1 Reanalysis with Recoding. PASAT data was reanalyzed to 
include the participant with elementary level education (n =1) by combining his data with 
other participants with a high school education. There were no major changes to data 
with the exception of high school education level having a nonmeaningful effect score 
which was previously a small effect size (rsp
2 =0.03); this same change was seen in the 




PASAT Trial 1 with and without Outliers  
  
 Model 1 Model 2 Model 3 Model 4  
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Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, Abbreviations were also used. High Sch = High School, 




PASAT Trial 2. Regression models were used on available data (n = 48). The 
full model for PASAT Trial 2 was nonsignificant, R2 = .171, 95% CI [.014, .328] F(7, 40) 
= 1.181, p = .335, adjusted R2 = .026. The first predictor block with age and education 
was nonsignificant, R2 = .136, F(4, 43) = 1.691, p = .170, adjusted R2 = .056; however, 
there was a medium effect. The addition of health condition on the second predictor 
block did not account for significant incremental variance in Trial 2, ∆F(1, 42) = .955, p 
= .334,  ∆R2 = .019; there was an approaching small effect. The addition of PTSD in the 
third block also failed to produce significant incremental variance in Trial 2, ∆F(1, 41) = 
.732, p = .397  ∆R2 = .015. The addition of the last block with fatigue level did not 
significantly contribute to the model with incremental variance, ∆F(1, 40) = .063, p = 
.803,  ∆R2 = .001. In the final model, age was associated with lower scores (rsp
 = -.126, 
95% CI [-.396, .164]) with a small effect (rsp
2 = 0.02). Education at the high school level 
(rsp
 = .12, 95% CI [-.170, .391]; rsp
2 = 0.01), college level (rsp
 = .094, 95% CI [-.195, 
.368]; rsp
2 = 0.01), and the doctoral level (rsp
 = .191, 95% CI [-.098, .451]; rsp
2 =0.04) were 
positively associated with the PASAT. Only education at the doctoral level produced a 
small meaningful effect.  Health condition (rsp
 = .022, 95% CI [-.264, .304]; rsp
2 = 0.00), 
PTSD symptoms (rsp
 = -0.091, 95% CI [-.366, .198]; rsp
2 = 0.01), and fatigue symptoms 
(rsp
 = -0.036, 95% CI [-.317, .251]; rsp










PASAT Trial 2 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2 B rsp2 B rsp2 B  rsp2 
Constant 41.834  47.452  41.018  40.760  
Age -.379 .03 -.429 .04 -.307 .02 -.301 .02 
Edu. Level         
 High School  10.291 .02 12.013 .01 10.062 .01 10.441 .01 
 Collegiate 7.664 .01 11.656 .00 7.404 .01 7.909 .01 
 Doctoral 17.019 .04 12.214 .03 16.350 .04 16.727 .04 
Condition a   -3.296 .02 .256 .00 .920 .00 
PTSD Level b     -.055 .01 -.046 .01 
Fatigue c       -.027 .00 
         
R2 .136  .155  .170  .171  
R2 adj .056  .055  .049  .026  
F 1.691  1.543  1.399  1.181  
Δ R2 .136  .019  .015  .001  
Δ F 1.691  .955  .732  .063  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total), c Fatigue (as designated by MFI General Fatigue); B indicates unstandardized 
coefficients, β indicates standardized coefficients, rsp2 indicates a semi-partial correlation squared 
 
PASAT Trial 2 Reanalysis without Outliers. The overall model of age, 
education, condition, PTSD symptoms and fatigue (n = 46) did not significantly predict 
changes on the second trial of the PASAT when analyzed without outliers, R2 = .145, 
95% CI [-.018, .308], F(7, 38) = 1.146, p = .356, adjusted R2 = .022. There were no 
changes in any of the hierarchical models. The first model (R2 = .145) held a medium 
effect size. However, the second model (Δ R2 = .018) approached a small effect with the 
addition of health condition. Semi-partial correlation interpretation also did not change 
without outliers.  
PASAT Trial 2 Reanalysis with Recoding. Reanalysis with the original data 
revealed that Model 1 R2 and Model 1 Δ R2 with age and education had a small effect (R2 
= .120) which was previously a medium effect size (R2 = .136).  Additionally, Model 2 Δ 
R2 was interpreted as a small effect size (Δ R2 = .026), which was previously non-
meaningful (Δ R2 = .019). Without outliers, there were similar results in that Model 1 R2 




Δ R2 was interpreted as a small effect (.026) over a non-significant effect (.018). 
Table 6 
PASAT Trial 2 with and without Outliers  
  
 Model 1 Model 2 Model 3 Model 4  
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Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, Abbreviations were also used. High Sch = High School, 
Cond. = Condition. rsp2 indicates a semi-partial correlation squared 
 
PASAT Trial 3 Analysis. The full model for PASAT Trial 3 (n = 48) was 
nonsignificant, R2 = .194, 95% CI [.032, .356], F(7, 40) = 1.375, p = .242, adjusted R2 = 
.053. The first predictor block (i.e., age and education) was nonsignificant, R2 = .136, F(4, 
43) = 1.691, p = .170, adjusted R2 = .056; a medium effect was observed. The addition of 
health condition in Block 2 did not account for significant incremental variance in Trial 
3, ∆F(1, 42) = .713, p = .403,  ∆R2 = .014. The third block, with PTSD symptoms, also 




∆R2 = .004. The addition of the last block with fatigue level did not significantly 
contribute to the model with incremental variance, ∆F(1, 40) = .736, p = .396,  ∆R2 = 
.015. For the overall model, age did not produce a meaningful effect (rsp
 = -.107, 95% 
CI[-.380, .183], rsp
2 = 0.01). Education at the high school level (rsp
 = .264, 95% CI [-.022, 
.510]; rsp
2 = 0.07), college level (rsp
 = .217, 95% CI [-.072, .472]; rsp
2 = 0.05), and the 
doctoral level (rsp
 = .257, 95% CI [-.029, .504]; rsp
2 =0.07) were positively associated with 
the PASAT and all produced a small meaningful effect. Health condition (rsp
 = .031, 95% 
CI [-.255, .312]; rsp
2 = 0.00), PTSD symptoms (rsp
 = -0.001, 95% CI [-.285, .283]; rsp
2 = 
0.00), and fatigue symptoms (rsp
 = -0.112, 95% CI [-.384, .178]; rsp
2 = 0.01) did not show 
a statistical or meaningful association. 
Table 7 
PASAT Trial 3 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2 B rsp2 B rsp2 B  rsp2 
Constant 24.882  28.964  26.090  25.349  
Age -.253 .02 -.289 .02 -.234 .01 -.218 .01 
Edu. Level         
 High School  19.332 .08 17.520 .06 18.532 .06 19.617 .07 
 Collegiate 14.805 .05 13.429 .04 14.159 .04 15.608 .05 
 Doctoral 18.918 .07 17.416 .06 18.040 .06 19.122 .07 
Condition a   -2.396 .01 -.809 .00 1.097 .00 
PTSD Level b     -.024 .00 .000 .00 
Fatigue c       -.077 .01 
         
R2 .161  .175  .179  .194  
R2 adj .083  .077  .059  .053  
F 2.064  1.783  1.491  1.375  
Δ R2 .161  .004  .004  .004  
Δ F 2.064  .713  .204  .736  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total), c Fatigue (as designated by MFI General Fatigue); B indicates unstandardized 
coefficients, β indicates standardized coefficients rsp2 indicates a semi-partial correlation squared 
 
PASAT Trial 3 Reanalysis without Outliers. The overall model of age, 
education, condition, PTSD symptoms and fatigue (n = 46) did not produced significance 
within the third trial of the PASAT without outliers, R2 = .172, 95% CI [.013, 331] F(7, 




model was approaching a meaningful effect (Δ R2 = .018). As before, the first model (R2 
= .172) held a medium effect size. Squared semi-partial correlations showed a difference 
from the previous analysis as in the second model the health status of the veteran (i.e., 
either GWI or healthy control) approached a meaningful effect with a negative 
association for PASAT Trial 3 scores (rsp
 = -.134, 95% CI [-.408, .163]; rsp
2 =0.018). 
PASAT Trial 3 Reanalysis with Recoding. Model 1 R2, Model 1 Δ R2 , Model 2 
R2, Model 3 R2, and Model 4 R2 returned a small effect (Model 1 R2/Δ R2 = .086, Model 
2 R2 = .116, Model 3 R2 = .116,  Model 4 R2 = .124) which was previously a medium 
effect size (Model 1R2/ Δ R2 = .161, Model 2 R2 = .175, Model 3 R2 = .179,  Model 4 R2 
= .174).  Additionally, Model 2 Δ R2 reanalysis resulted in a small effect size (.030) 
which was previously non-meaningful (.004). For the final model semi-partial correlates, 
reanalysis showed differences in age, (rsp
2 = 0.036, previously non-significant), high 
school level of education (non-significant, previously rsp
2 = .07) and doctoral level of 
education (non-significant, previously rsp
2 = .07).  
Without outliers, there were similar results in that Model 1 R2, Model 1 Δ R2 , 
Model 2 R2, Model 3 R2, and Model 4 R2 revealed a small effect (Model 1 R2/Δ R2 = 
.089, Model 2 R2 = .126, Model 3 R2 = .126,  Model 4 R2 = .127) which was previously a 
medium effect size (Model 1R2/ Δ R2 = .172, Model 2 R2 = .190, Model 3 R2 = .192,  
Model 4 R2 = .196).   Model 2 Δ R2 reanalysis resulted in a small effect size (.037) which 
was previously non-meaningful (.018). Lastly, semi-partial correlation effect sizes 
revealed that doctoral education was now non-meaningful, which was previously a small 







PASAT Trial 3 with and without Outliers  
  
 Model 1 Model 2 Model 3 Model 4  
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Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, Abbreviations were also used. High Sch = High School, 
Cond. = Condition. rsp2 indicates a semi-partial correlation squared 
 
PASAT Trial 4 Analysis. The full model for PASAT Trial 4 (n = 48) was 
nonsignificant, R2 = .238, 95% CI [.068, .408], F(7, 40) = 1.784, p = .117, adjusted R2 = 
.105. The first predictor block with age and education was nonsignificant, R2 = .184, F(4, 
43) = 2.426, p = .062, adjusted R2 = .108; a medium effect was observed. The addition of 
health condition in the second predictor block did not add significant incremental 
variance in Trial 4, ∆F(1, 42) = 1.023, p = .318,  ∆R2 = .019; however, an approaching 




produce significant incremental variance in Trial 4, ∆F(1, 41) = 1.801, p = .187  ∆R2 = 
.034; a small effect was observed. The addition of the fatigue in the last block did not 
significantly contribute to the model with incremental variance, ∆F(1, 40) = .048, p = 
.828  ∆R2 = .001. For the overall model, age did not produce a meaningful effect (rsp
 = -
.022, 95% CI [-.304, .264]; rsp
2 = 0.09). Education showed a small effect across all levels 
including high school (rsp
 = .353, 95% CI [.077, .579]; rsp
2 = 0.12), college  (rsp
 = .31, 95% 
CI [.028, .546]; rsp
2 = 0.10), and the doctoral level (rsp
 = .348, 95% CI [.071, .575]; rsp
2 
=0.12) which were positively associated with scores. PTSD symptoms (rsp
 = -.176, 95% 
CI [-.438, .114]; rsp
2 = 0.03) showed a small meaningful effect and was negatively 
associated with scores. Health condition (rsp
 = .035, 95% CI [-.252, .316]; rsp
2 = 0.00), and 
fatigue symptoms (rsp
 = 0.03, 95% CI [-.256, .311]; rsp
2 = 0.00) did not show a statistical 
or meaningful association. 
Table 9 
PASAT Trial 4 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2 B rsp2 B rsp2 B  rsp2 
Constant 8.339  12.549  5.335  5.496  
Age -.135 .01 -.172 .01 -.035 .00 -.039 .00 
Edu. Level         
 High School  22.546 .13 20.677 .11 23.217 .13 22.981 .12 
 Collegiate 19.438 .10 18.019 .09 19.851 .10 19.536 .10 
 Doctoral 22.928 .13 21.378 .11 22.946 .13 22.711 .12 
Condition a   -2.470 .02 1.512 .00 1.098 .00 
PTSD Level b     -.061 .03 -.066 .03 
Fatigue c       .017 .00 
         
R2 .184  .204  .237  .238  
R2 adj .108  .109  .125  .105  
F 2.426  2.146  2.123  1.784  
Δ R2 .184  .019  .034  .001  
Δ F 2.426  1.023  1.801  .048  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total), c Fatigue (as designated by MFI General Fatigue); B indicates unstandardized 
coefficients, β indicates standardized coefficients  
 
PASAT Trial 4 Reanalysis without Outliers. The full model of age, education, 




continued to be non-significant, R2 = .248, 95% CI [.075, .421], F(7, 38) = 1.789, p = 
.118, adjusted R2 = .109. Additionally, subsequent models including variables of interests 
were not significant. However, the overall effect of Model 1 with age and education 
levels had a medium effect (R2 = .198) and significance (p = .054). The second model, 
including health condition, somewhat approached a clinical effect (Δ R2 = .018), pointing 
towards a possible trend with GWI diagnosis and poorer performance on PASAT. The 
third model, which included PTSD symptoms, continued to hold a small effect regarding 
model change (Δ R2 = .028). For the last model, there was a change in the magnitude as 
the high school education changed from a small to a medium effect (rsp
2 = .13). 
PASAT Trial 4 Reanalysis with Recoding. Model 1 R2, Model 1 Δ R2 , Model 2 
R2, Model 3 R2, and Model 4 R2 had a small effect (Model 1 R2/Δ R2 = .051, Model 2 R2 
= .096, Model 3 R2 = .108,  Model 4 R2 = .113) which was previously interpreted as a  
medium effect size (Model 1R2/ Δ R2 = .184, Model 2 R2 = .204, Model 3 R2 = .237,  
Model 4 R2 = .238).  Additionally, Model 2 Δ R2 reanalysis resulted in a small effect size 
(.046) which was previously non-meaningful (.019); however, Model 3 Δ R2 reanalysis 
returned a non-significant effect size (.012), which was beforehand interpreted as a small 
effect (.034). For the final model semi-partial correlates, reanalysis showed differences in 
high school level of education (non-significant, previously rsp
2 = .12), doctoral level of 
education (non-significant, previously rsp
2 = .12), and PTSD symptoms (non-significant, 
previously rsp
2 = .03).  
When analyzed without outliers, there were similar results in that Model 1 R2, 
Model 1 Δ R2 , Model 2 R2, Model 3 R2, and Model 4 R2 revealed a small effect (Model 1 




previously medium effect size (Model 1R2/ Δ R2 = .198, Model 2 R2 = .216, Model 3 R2 = 
.244,  Model 4 R2 = .248).  Furthermore, Model 2 Δ R2 reanalysis returned a small effect 
size (.044) which was previously non-meaningful (.018) and Model 3 Δ R2 returned a 
non-significant effect which was previously small (.028).  For the final model semi-
partial correlates, reanalysis showed differences in high school level of education (non-
significant, previously rsp
2 = .13), doctoral level of education (non-significant, previously 
rsp
2 = .12), and PTSD symptoms (non-significant, previously rsp
2 = .03).  
Table 10 
PASAT Trial 4 with and without Outliers  
  
 Model 1 Model 2 Model 3 Model 4  
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Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, β indicates standardized coefficients. Abbreviations were 





Figure 1. The change in R2 across all four PASAT trials for GWI, PTSD and Fatigue. Health Condition or 
GWI appears to be more meaningful in the second and fourth trials, while PTSD only approaches a 
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Effect Size R2 Change
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Figure 2. Coefficient effect size as plotted by each trial for Model 1 which included age and education level 
(high school, college, doctorate). Age showed a meaningful effect until Trial 4, which was the most 
demanding. Regarding education level, a doctoral level of education demonstrated a meaningful effect 
across all trials. A high school level of education showed a meaningful effect for all trials except Trial 2. A 
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Figure 3. Coefficient effect size as plotted by each trial for Model 2 which included age, education level 
(high school, college, doctorate), and health condition (GWI or healthy control). As in the first model, age 
held a meaningful effect until the last trial. Education levels demonstrated the same patterns as in Model 















PASAT 1 PASAT 2 PASAT 3 PASAT 4
Model 2: Age, Education, and GWI Effect Sizes 





Figure 4. Coefficient effect size as plotted by each trial for Model 3 which included age, education level 
(high school, college, doctorate), health condition (GWI or healthy control), and PTSD symptom level. Age 
was only meaningful for the first trial. For education levels, high school was meaningful within all trials 
except Trial 2 whereas college was only meaningful during the last two trials. Doctoral level of education 
was meaningful across all trials. Health condition did not demonstrate a meaningful effect. Finally, PTSD 












PASAT 1 PASAT 2 PASAT 3 PASAT 4
Model 3: Age, Education, GWI, and PTSD Effect 
Sizes





Figure 5. Coefficient effect size as plotted by each trial for the full model comprised of age, education 
level (high school, college, doctorate), health condition (GWI or healthy control), PTSD symptom 
level, and fatigue level. As in Model 3, age was only meaningful for the first trial. Education level 
continued to show the same trends as in Model 3. Health condition continued to not demonstrate a 
meaningful effect. However, PTSD continued to show a meaningful effect in Trial 4 of the PASAT. 
Fatigue did not produce any meaningful effects.   
 
Fatigue Results by Condition and Cytokines  
Another hierarchical regression model was used on available data (n = 57) to 
investigate if condition and cytokines (as measured by levels of IL-4 and IL-10) would 
predict how veterans reported fatigue. Fatigue, as measured by the MFI, was divided 
between five subscales: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced 
Motivation, and Reduced Activity. In the second set of hierarchical regression models, all 
the subscales were analyzed in separate models. Predictor blocks were held constant 
across models: Block 1 (GWI) and Block 2 (IL-4, IL-10). Tables 11 through 19 present 
selected statistical information from the analyses.  
General Fatigue. Models (n = 57) were designed to first evaluate condition (GWI 
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General Fatigue was significant, R2 = .600, 95% CI [.454, .746], F(3, 53) = 26.451, p < 
.001, adjusted R2 = .577. However, the addition of IL-4 and IL-10 in the second predictor 
block did not lead to a statistically significant incremental increase, Δ F(2, 53) = 1.148, p 
= .325. Δ R2 = 017, Coefficient semi-partial correlations revealed a positive association 
with heath condition (rsp
 = .763, 95% CI [.626, .854] rsp
2 =0.582) but not for separate 
interleukins. 
Table 11 
MFI General Fatigue 
 Model 1 Model 2 
Variable B rsp2 B rsp2 
Constant 17.559  16.898  
Condition a 47.096** .58 48.092** .59 
IL-4   5.449 .01 
IL-10   1.381 .01 
     
R2 .582**  .600**  
R2 adj .575**  .577**  
F 76.647**  26.451**  
Δ R2 .582**  .017  
Δ F 76.647**  1.148  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), B indicates unstandardized 
coefficients, rsp2 indicates squared semi-partial correlations  
 
General Fatigue Reanalysis. A reanalysis was run with General Fatigue as the 
dependent variable on remaining data (n = 55) without outlier identified in the previous 
analysis. The final model including health condition and both cytokines was significantly 
associated with General Fatigue, R2 = .673, 95% CI [.545, .801], F(3, 51) = 35.048, p < 
.001, adjusted R2 = .654. The addition of IL-4 and IL-10 also showed a small meaningful 
effect in ΔR2= .049. There were no changes in the interpretation of coefficient semi-








MFI General Fatigue with and without Outliers 
 Model 1 Model 2 
Variable B rsp2 B rsp2 
Constant 17.559(15.740**)  16.898(13.760**)  
Condition a 47.096**(49.289**) .58(.62) 48.092**(52.792**) .59(.62) 
IL-4   5.449(7.938) .01(.01) 
IL-10   1.381(3.388) .01(.01) 
     
R2 .582**(.625**)  .600**(.673**)  
R2 adj .575**(.618**)  .577**(.654**)  
F 76.647**(88.236**)  26.451**(35.048**)  
Δ R2 .582**(.625**)  .017(.049*)  
Δ F 76.647**(88.236**)  1.148(3.797*)  
Note. *p < .05, **p <.001,a Case designation (GWI or Healthy Control), B indicates unstandardized 
coefficients, rsp2 indicates squared semi-partial correlations  
 
            Physical Fatigue. Models (n = 56) were designed to first evaluate condition 
(GWI versus healthy control) and, subsequently, the levels of cytokines. The overall 
model for Physical Fatigue was significant, R2 = .599, 95% CI [.452, .746], F(3, 52) = 
25.862, p < .001, adjusted R2 = .576. However, the addition of IL-4 and IL-10 in Block 2 
did not show a statistically significant incremental value Δ F(2, 52) = 2.387, p = .102, Δ 
R2 = .037. However, the change did point towards a small effect. Coefficient semi-partial 
correlations within the full model showed a large effect size associated with health status 
(rsp
 = .765, 95% CI [.629, .856]; rsp
2 =0.585) indicating that veterans with GWI endorse 
higher levels of Physical Fatigue over healthy controls; however, IL-4 (rsp
 = .094, 95% CI 
[-.173, .348]; rsp
2 =0.009) and IL-10 (rsp
 = .119, 95% CI [-.149, .370, .546];  rsp
2 =0.014) 










MFI Physical Fatigue 
 Model 1 Model 2 
Variable B rsp2 B rsp2 
Constant 13.117  11.763  
Condition a 47.227** .56 49.030** .59 
IL-4   6.212 .01 
IL-10   2.676 .01 
     
R2 .562**  .599**  
R2 adj .554**  .576**  
F 69.255**  25.862**  
Δ R2 .562**  .037  
Δ F 69.255**  2.387  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), B indicates unstandardized 
coefficients, rsp2 indicates squared semi-partial correlations  
 
Physical Fatigue Reanalysis. A reanalysis also run for Physical Fatigue without 
outliers on remaining data (n = 54). The final model including health condition and both 
cytokines was significantly associated with Physical Fatigue, R2 = .677, 95% CI [.549, 
.805], F(2, 50) = 34.969, p < .001, adjusted R2 = .658. The addition of IL-4 and IL-10 
also showed a small meaningful effect in ΔR2= .088. Additionally, coefficient semi-
partial correlations changed as IL-10 showed a small positive association without outliers 
(rsp
 = .211, 95% CI [-.060, .453]; rsp
2 =0.04). 
Table 14 
MFI Physical Fatigue with and without Outliers 
 Model 1 Model 2 
Variable B rsp2 B rsp2 
Constant 13.117*(11.698*)  11.763(7.704*)  
Condition a 47.227**(49.164**) .56 (.58) 49.030**(55.256**) .59(.65) 
IL-4   6.212(5.607) .01(.01) 
IL-10   2.676(6.555*) .01(.04) 
     
R2 .562**(.590**)  .599**(.677**)  
R2 adj .554**(.582**)  .576**(.658*)  
F 69.255**(74.694**)  25.862**(34.696**)  
Δ R2 .562**(.590**)  .037(.088*)  
Δ F 69.255**(76.694**)  2.387(6.790*)  
Note. *p < .05, **p <.001,a Case designation (GWI or Healthy Control), B indicates unstandardized 
coefficients, rsp2 indicates squared semi-partial correlations  
 
Mental Fatigue. The full model (n= 58) was significant, R2 = .532, 95% CI [.372, 




second predictor block did not return significance, Δ F(2, 54) = 1.634, p = .205, Δ R2= 
.028. However, there was a small effect. Semi-partial correlations from the full model 
returned a large effect size concerning health status (rsp
 = .683, 95% CI [.516, .800]; rsp
2 
=0.466) with a positive association between GWI and increased Mental Fatigue scores. 
Additionally, there was a small and positive effect shown in IL-4 (rsp
 = .158, 95% CI [-
.105, .400]; rsp
2 =0.025). IL-10 (rsp
 = -.113, 95% CI [-.361, .150]; rsp
2 =0.013) did not 
demonstrate a meaningful effect. 
Table 15 
MFI Mental Fatigue  
 Model 1 Model 2 
Variable B rsp2 B rsp2 
Constant 15.476  17.266  
Condition a 49.246** .50 48.201** .47 
IL-4   11.703 .02 
IL-10   -2.834 .01 
     
R2 .503**  .532**  
R2 adj .494**  .506**  
F 56.725**  20.425**  
Δ R2 .503**  .028  
Δ F 56.725**  1.634  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), B indicates unstandardized 
coefficients, rsp2 indicates squared semi-partial correlations  
 
Mental Fatigue Reanalysis. A reanalysis also run for Mental Fatigue without 
outliers on remaining data (n = 56). The final model including health condition and both 
cytokines was significantly associated with Mental Fatigue, R2 = .567, 95% CI [.412, 
.722] F(3, 52) = 22.708, p < .001, adjusted R2 = .524. The addition of IL-4 and IL-10 
continued to evidence a small meaningful effect in ΔR2= .033. Coefficient semi-partial 








MFI Mental Fatigue with and without Outliers 
 Model 1 Model 2 
Variable B rsp2 B rsp2 
Constant 15.476(14.197)  17.266(15.039)  
Condition a 49.246**(51.607**) .50(.53) 48.201**(51.241**) .47(.47) 
IL-4   11.703(14.613*) .02(.03) 
IL-10   -2.834(-1.940) .01(.00) 
     
R2 .503**(.535**)  .532**(.567**)  
R2 adj .494**(.526**)  .506**(.542**)  
F 56.725**(62.028**)  20.425**(22.708**)  
Δ R2 .503**(.535**)  .028(.033)  
Δ F 56.725**  1.634(1.053)  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), B indicates unstandardized 
coefficients, rsp2 indicates squared semi-partial correlations  
 
Reduced Activity. The full model (n = 56) was significant, R2 = .491, 95% CI 
[.322, .660], F(2, 52) = 16.752, p < .001, adjusted R2 = .462. The second block, with the 
addition of cytokines, was nonsignificant, Δ F(3, 52) = .104, p = .901, ΔR2 = .002. Partial 
correlation analysis showed a large effect size for condition with a positive association (rsp
 
= .700, 95% CI [.536, .813]; rsp
2 =0.49) indicating that veterans with GWI endorse higher 
levels of reduced activity. No other meaningful effects were identified.  
Table 17 
MFI Reduced Activity  
 Model 1 Model 2 
Variable B rsp2 B rsp2 
Constant 14.583  13.919  
Condition a 39.732** .49 40.657** .45 
IL-4   -.890 .00 
IL-10   1.230 .00 
     
R2 .489**  .491**  
R2 adj .480**  .462**  
F 51.765**  16.752**  
Δ R2 .489**  .002  
Δ F 51.765**  .104  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), B indicates unstandardized 
coefficients, rsp2 indicates squared semi-partial correlations  
 
Reduced Activity Reanalysis. A reanalysis was conducted with Reduced 
Activity without outliers on available data (n = 55). The final model including health 




.542, 95% [.381, .703] F(3, 51) = 20.081, p < .001, adjusted R2 = .515. The addition of 
IL-4 and IL-10 continued to not provide any meaningful effect, ΔR2= .008. The 
interpretation of coefficient semi-partial correlations did not change.  
Table 18 
MFI Reduced Activity with and without Outliers 
 Model 1 Model 2 
Variable B rsp2 B rsp2 
Constant 14.583(12.808)  13.919(12.345)  
Condition a 39.732**(41.507**) .49(.53) 40.657**(42.43**) .45(.49) 
IL-4   -.890(3.899) .00(.00) 
IL-10   1.230(.736) .00(.00) 
     
R2 .489**(.534**)  .491**(.542**)  
R2 adj .480**(.525**)  .462**(.515**)  
F 51.765**(60.708**)  16.752**(20.081**)  
Δ R2 .489**(.534**)  .002(.008)  
Δ F 51.765**(60.708**)  .104(.426)  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), B indicates unstandardized 
coefficients, rsp2 indicates squared semi-partial correlations  
 
Reduced Motivation. The final model (n= 57) was statistically significant, R2 = 
.502, 95% CI [.336, .668], F(3, 53) = 17.818, p < .001, adjusted R2 = .474. The addition 
of the interleukin variables did not return a significant change or had an effect of 
meaningful magnitude, Δ F(2, 53) = .469, p = .628, ΔR2= .009. Coefficient analysis 
revealed a large effect size regarding condition status (rsp
 = .702, 95% CI [.540, .814]; rsp
2 
=0.493) indicating that GWI diagnosis is positively associated with higher levels of 











MFI Reduced Motivation 
 Model 1 Model 2 
Variable B rsp2  B rsp2  
Constant 11.728  12.892  
Condition a 41.466** .49 40.390** .45 
IL-4   2.055 .00 
IL-10   -1.986 .01 
     
R2 .493**  .502**  
R2 adj .484**  .474**  
F 53.552**  17.818**  
Δ R2 .493**  .009  
Δ F 53.552**  .469  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), B indicates unstandardized 
coefficients, rsp2 indicates squared semi-partial correlations  
 
             Reduced Motivation Reanalysis. The final model (n =55) analyzed without 
outliers and comprised of condition status followed by cytokines (i.e., IL-10, IL-4) on the 
prediction of self-report of Reduced Motivation was statistically significant, R2 = .550, 95% 
CI [.391, .709], F(3, 51) = 20.789, p < .001, adjusted R2 = .524. The addition of the 
interleukin variables did not return a significant change or had meaning, Δ R2= .003, F(2, 
51) = .192, p = .826.  Coefficient analysis revealed a large effect size regarding condition 
status (rsp
 = .707, 95% CI [.544, .819];  rsp
2 =0.50) which was positively associated with 
Reduced Motivation. The interleukin variables did not produce a meaningful effect.  
Table 20 
MFI Reduced Motivation with and without Outliers 
 Model 1 Model 2 
Variable B rsp2  B rsp2  
Constant 11.728(10.416)  12.892(9.745)  
Condition a 41.466**(44.181**) .49(.54) 40.390**(45.248**) .45(.54) 
IL-4   2.055(1.293) .00(.00) 
IL-10   -1.986(1.122) .01(.00) 
     
R2 .493**(.547**)  .502**(.550)  
R2 adj .484**(.538**)  .474**(.524)  
F 53.552**(63.961**)  17.818**(20.789**)  
Δ R2 .493**(.547**)  .009(.003)  
Δ F 53.552**(63.961**)  .469(.192)  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), B indicates unstandardized 






Figure 6. This bar chart demonstrates the R2 or change as a measure of effect size. While GWI status had a 
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Figure 7. This bar chart demonstrates semi-partial squared effect sizes for each coefficient. As with the 
overall model, GWI was the most powerful predictor of reporting different areas of fatigue. Cytokines were 
less influential, with interleukin 4 showing a small but meaningful impact in Mental Fatigue.  
 
Summary of the A Priori Results 
            Overall, the first analysis of the first hypothesis investigating the impact of GWI 
versus healthy control, PTSD, and fatigue over age and education on the PASAT, did not 
demonstrate significant results overall.  In general, age and education demonstrated 
virtually consistent effects on across the PASAT trials. The diagnosis of GWI was 
approaching a meaningful effect in later trials, particularly Trials 2 and 4. Finally, trauma 
did demonstrate a meaningful effect within the last trial of the PASAT. However, the 
addition of fatigue was not contributing to the model in a meaningful way. This finding is 
consistent with Johnson, Lange, DeLuca, Korn and Natelson (1997) who found that 
individuals with diagnoses associated with higher levels of fatigue including chronic 
fatigue syndrome, was not significantly differ in comparison to healthy controls.  




















condition (GWI versus healthy control) and interleukins IL-4 and IL-10 found that GWI 
status was the most consistent variable associated with higher levels of self-reported 
fatigue levels. In regard to interleukins, results were inconsistent showing possibly trends 
towards elevated IL-10 with physical fatigue and elevated IL-4 with increased mental 
fatigue; therefore, it was consistent with Broderick et al. (2017) that found varied results. 
Nevertheless, it did not indicate a clear pattern.  
To further investigate possible contributions to PASAT scores, the researcher 
conducted a post analysis for PASAT trials.  Results concerning the MFI was more 
varied and was associated with changes in interleukin 4 (IL-4), interleukin 12 (IL-12), 
and IL-10. GWI, particularly in models of higher stress, has been associated with changes 
in pro-inflammatory markers (Broderick et al., 2011; Symlie et al. 2013; Whistler et al., 
2009). Additionally, PTSD has been associated with inflammation and inflammatory 
mediators (Wang & Young, 2016). A correlation between variables of interest and 
available cytokines was conducted to investigate possible associations with PASAT 
scores. Correlations returned significance for cytokines with PASAT performance 
including tumor necrosis factor alpha (TNFα  PASAT Trial 3 r = -.377) and interferon 
gamma (INFγ PASAT Trial 2 r = -.357; PASAT Trial 3 r = -.359; PASAT Trial 4 r = -
.342). An additional analysis was run to include interleukin 6 (IL-6: PASAT Trial 3 r = -
.37) and interleukin 8 (IL-8: Trial 3 r = -.43; Trial 4 r =-.38). Therefore, the researcher 
investigated a model that removed fatigue as a variable and adding cytokines within the 
hierarchical analysis. Therefore, the model was designed to investigate health condition 
(GWI versus healthy control), cytokines (TNFα, INFγ followed by IL-6 and IL-8) and 






            Correlation. Correlations were run on all variables of interest including 
demographic variables, PASAT Trials, MFI scores, and available cytokines on available 
data to investigate any possible associations cytokines have on PASAT scores (n = 34). 
Correlations are reported in the appendices.  
PASAT Results by Condition, TNFα/INFγ , and PTSD Symptoms  
Another hierarchical regression model was utilized to investigate if condition 
(GWI status), cytokines (i.e., TNFα and/or INFγ), and PTSD symptoms would predict 
how veterans performed on a measure of working memory and attention (PASAT) over 
and above demographic factors. Predictor blocks were held constant across models: 
Block 1 (Age and Education), Block 2(GWI), Block 3 (TNFα,  INFγ,) and Block 4 
(PTSD symptoms). Tables 22 through 28 present selected statistical information from the 
analyses.  
            PASAT Trial 1. Regression models were used on available data (n = 48) to test if 
GWI status, TNFα and/or INFγ, and PTSD symptoms. The full model for PASAT Trial 1 
was nonsignificant, R2 = .257, 95% CI [.089, .425], F(8, 39) = 1.683, p = .134, adjusted 
R2 = .104. The first predictor block including age and education had a medium effect and 
approached significance, R2 = .164, F(4, 43) = 2.104, p = .097, adjusted R2 = .086. The 
addition of condition did not contribute significantly by means of incremental variance, 
ΔF(1, 42) = .393, p = .534, Δ R2= .008. Next, the addition of cytokines did not produce 
significant incremental variance but had a small effect, ΔF(2, 40) = 2.277, p = .116, Δ 




ΔF(1, 39) = .028, p = .867, Δ R2= .001. In the final model, squared semi-partial 
correlations showed a negative association and small effect with age (rsp
 = -.227, 95% CI 
[-.480, .061]; rsp
2 =0.05). Positive associations and a small effect were produced regarding 
education at the high school level (rsp
 = .158, 95% CI [ -.132, .423]; rsp
2 =0.02), collegiate 
level (rsp
 = .148, 95% CI [-.142, .415]; rsp
2 =0.02),  and the doctoral level (rsp
 = .224, 95% 
CI [-.064, .478]; rsp
2 =0.05). Furthermore, the cytokines also showed a negative 
association with a small effect size in INFγ (rsp
 = -.18, 95% CI [-.442, .110]; rsp
2 =0.03) 
and TNFα  (rsp
 = -.20, 95% CI [ -.458, .089]; rsp
2 =0.04).  
Table 21 
PASAT Trial 1Post Hoc 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2  B rsp2  B rsp2  B  rsp2  
Constant 50.95  54.37  51.28  49.76  
Age -.66 .07 -.68 .06 -.67 .07 -.64 .05 
Edu. Level         
 High School  14.6 .02 12.99 .02 15.14 .02 15.64 .02 
 Collegiate 12.27 .02 11.01 .01 13.87 .02 14.20 .02 
 Doctoral 20.98 .05 19.55 .04 22.08 .05 22.34 .05 
Condition a   -2.36 .01 -1.44 .00 -.66 .00 
INFγ     -4.35 .04 -4.23 .03 
TNFα     -2.37 .04 -2.34 .04 
PTSD Level b       -.012 .00 
         
R2 .164  .171  .256  .257  
R2 adj .086  .073  .126  .104  
F 2.104  1.738  1.968  1.683  
Δ R2 .164  .008  .085  .001  
Δ F 2.104  .393  2.277  .028  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial 
correlations  
 
PASAT Trial 1 Reanalysis without Outliers. Assumption testing of the data 
revealed two potential outliers which were excluded for the following analysis (n = 46). 
The analysis interpretation did not change with the full model for PASAT 1 as it 
remained nonsignificant (see Table 22 for comparison values). However, the effect sizes 




significant with a small effect (∆R2 = .091). Coefficients as reported with the squared 
semi-partial correlations did not produce a notable change in values and were interpreted 
in the same manner. 
PASAT Trial 1 Reanalysis with Recoding. PASAT data was reanalyzed to 
include the participant with elementary level education (n =1) by combining his data with 
other participants with a high school education. There were no major changes to data 
with the exception of high school education level having a nonmeaningful effect score 
which was previously a small effect size in both the original data (rsp
2 =0.02) and data 
without outliers (rsp



















PASAT Trial 1 with and without Outliers Post Hoc 
  
 Model 1 Model 2 Model 3 Model 4  
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Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial correlations 
Abbreviations were also used. High Sch = High School, Cond. = Condition.  
 
PASAT Trial 2. The full model (n = 48) for PASAT Trial 2 was nonsignificant, 
R2 = .273, 95% CI[.104, .442], F(8, 39) = 1.833, p = .1, adjusted R2 = .124. The first 
predictor block with age and education demonstrated a medium effect but was 
nonsignificant, R2 = .135, F(4, 43) = 1.679, p = .172, adjusted R2 = .055. The addition of 
condition did not produce significant incremental variance, ΔF(1, 42) = 1.361, p = .250, 
Δ R2= .027; however, there was a small effect. Next, Block 3 with the addition of 




Δ R2= .108.  Finally, the addition of PTSD symptoms did not produce incremental 
variance, ΔF(1, 39) = .170, p = .682, Δ R2= .003. In the final model, squared semi-partial 
correlations revealed a negative association and small effect in age (rsp
 = -.162, 95% CI [-
.427, .128]; rsp
2 =0.03). Positive associations and a small effect were produced regarding 
education at the doctoral level (rsp
 = .197, 95% CI [-.092, .456]; rsp
2 =0.04). All other 
levels of education did not indicate a meaningful effect. The cytokines showed a negative 
association with a small effect size in INFγ (rsp
 = -.169, 95% CI [-.432, .121]; rsp
2 =0.03) 
and TNFα  (rsp
 = -.246, 95% CI [-.496, .041]; rsp
2 =0.06). GWI and PTSD did not produce 
meaningful effects.  
Table 23 
PASAT Trial 2 Post Hoc 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2  B rsp2  B rsp2  B  rsp2  
Constant 44.72  50.38  47.51  44.26  
Age -.44 .04 -.48 .05 -.47 .04 -.4 .03 
Edu. Level         
 High School  9.16 .01 6.51 .01 8.63 .01 9.7 .01 
 Collegiate 7.39 .01 5.29 .00 7.99 .01 8.69 .01 
 Doctoral 16.79 .04 14.42 .03 16.81 .04 17.38 .04 
Condition a   -3.91 .03 -3.15 .02 -1.48 .00 
INFγ     -3.79 .03 -3.52 .03 
TNFα     -2.61 .06 -2.55 .06 
PTSD Level b       -.03 .00 
         
R2 .135  .162  .270  .273  
R2 adj .055  .063  .142  .124  
F 1.679  1.627  2.115  1.833  
Δ R2 .135  .027  .108  .003  
Δ F 1.679  1.361  2.956  .170  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial 
correlations  
 
PASAT Trial 2 Reanalysis without Outliers. The overall model of age, 
education, condition, cytokines, and PTSD symptoms (n = 46) did not significantly 
predict changes on the second trial of the PASAT when analyzed without outliers, R2 = 




first model (R2 = .135) with age and education continued to hold a medium effect size 
overall. In addition, the second model (Δ R2 = .027) had the same small effect with the 
addition of health condition. The third model demonstrated a small effect overall (Δ R2 = 
.103). The fourth model, with the PTSD as a covariate, was not significant. The 
interpretations of covariates remained the same.  
PASAT Trial 2 Reanalysis with Recoding. Reanalysis with the original data 
returned a significant effect with Model 3 (p = .044) with age, education, health 
condition, and cytokines, which was previously not significant. Additionally, Model 1 
and Model 1 Δ R2 with age and education had a small effect (R2 = .123) which was 
previously a medium effect size (R2 = .135). Without outliers, there were similar results 
in that the Model 3 p value was significant (p = .055). Model 1 and Model 1 Δ R2 had a 

















PASAT Trial 2 with and without Outliers Post Hoc 
  
 Model 1 Model 2 Model 3 Model 4  
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Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial correlations 
Abbreviations were also used. High Sch = High School, Cond. = Condition.  
 
PASAT Trial 3 Analysis. The full model (n = 48) for PASAT Trial 3 was 
nonsignificant, R2 = .291, 95% CI [.120, .462], F(8, 39) = 2.004, p = .072, adjusted R2 = 
.146. The first predictor block (i.e., age and education) produced a medium effect; 
however, the model was nonsignificant, R2 = .146, F(4, 43) = 1.834, p = .140, adjusted R2 
= .066. The addition of condition did not indicate incremental variance, ΔF(1, 42) = 




the addition of cytokines showed a statistically significant increase in variance with a 
small effect ΔF(2, 40) = 3.391, p = .044, Δ R2= .120.  Finally, the addition of PTSD 
symptoms did not produce incremental variance, ΔF(1, 39) = .001, p = .979, Δ R2= .000.  
Squared semi-partial correlations were interpreted for the full model. Age was negatively 
associated with scores and had a small effect (rsp
 = -.165, 95% CI [-.429, .125]; rsp
2 
=0.03). Positive associations and a small effect were produced regarding education at the 
high school level (rsp
 = .234, 95% CI [-.054, .486]; rsp
2 =0.05), at the collegiate level (rsp
 = 
.205, 95% CI [-.084, .462]; rsp
2 =0.04), and at the doctoral level (rsp
 = .246, 95% CI [-
.041, .496]; rsp
2 =0.04). The cytokines showed a negative association with scores and a 
small effect size, INFγ (rsp
 = -.149, 95% CI [-.416, .141]; rsp
2 =0.02) and TNFα  (rsp
 = -
.294, 95% CI [-.534, -.011]; rsp
2 =0.09). GWI and PTSD continued to not produce 
meaningful effects.  
Table 25 
PASAT Trial 3 Post Hoc 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2  B rsp2  B rsp2  B  rsp2  
Constant 28.68  33.39  31.11  30.94  
Age -.33 .03 -.37 .04 -.36 .04 -.35 .03 
Edu. Level         
 High School  17.85 .06 15.65 .05 17.51 .06 17.57 .05 
 Collegiate 14.44 .04 12.69 .03 14.89 .04 14.93 .04 
 Doctoral 18.62 .06 16.64 .05 18.61 .06 18.64 .06 
Condition a   -3.25 .03 -2.77 .02 -2.68 .01 
INFγ     -2.68 .02 -2.67 .02 
TNFα     -2.63 .09 -2.63 .09 
PTSD Level b       -.001 .02 
         
R2 .146  .171  .291  .291  
R2 adj .066  .073  .167  .146  
F 1.834  1.735  2.349  2.004  
Δ R2 .146  .025  .120  .000  
Δ F 1.834  1.288  3.391  .001  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total), c Fatigue (as designated by MFI General Fatigue); B indicates unstandardized 






PASAT Trial 3 Reanalysis without Outliers. The full model for PASAT Trial 3 
(n = 46) remained non-significant without outliers, R2 = .306, 95% CI [.133, .479], F(8, 
37) = 2.042, p = .068, adjusted R2 = .156. However, there was a meaningful effect in the 
first three models as before. The first model had a medium effect size (R2 = .151) with all 
parameters of the model (i.e., age and level of education) demonstrating a small effect 
(i.e., at or above .02).  The second model also had a small meaningful effect (Δ R2 = .031) 
with parameters of a small effect across age, education, and condition. Lastly, the third 
model retained its small effect (Δ R2 = .123) as well as all the included coefficients of 
age, educational level, health condition, and cytokines. The fourth model continued to 
demonstrate no significant or meaningful effect.  Additionally, coefficients did not 
change in their interpretation.  
PASAT Trial 3 Reanalysis with Recoding.  Model 1 R2, Model 1 Δ R2 , Model 
2 R2 returned a small effect (Model 1 R2/Δ R2 = .084, Model 2 R2 = .125) which was 
interpreted as a medium effect beforehand (Model 1 R2/Δ R2 = .146, Model 2 R2 = .171). 
Furthermore, Model 3 R2 and Model 4 R2 returned a medium effect (Model 3 R2 = .234, 
Model 4 R2 = .237) which was previously a large effect size (Model 3 R2 = .291, Model 4 
R2 = .291).  For the final model semi-partial correlates, reanalysis showed differences in 
high school level of education (non-significant, previously rsp
2 = .05), doctoral level of 
education (non-significant, previously rsp
2 = .06), health condition (rsp
2 = .02, previously 
non-significant),  and PTSD symptoms (non-significant, previously rsp
2 = .02). 
Analysis without outliers produced similar results in that Model 1 R2, Model 1 Δ 
R2 , returned a small effect (Model 1 R2/Δ R2 = .084) which previously a medium effect 




.247, Model 4 R2 = .252) which was previously large (Model 3 R2 = .306, Model 4 R2 = 
.306).  Lastly, semi-partial correlation effect sizes revealed changes in high school 
educational levels (non-significant, previously rsp
2 = .05), doctoral education levels (non-
significant, previously rsp
2 = .06), and health condition (rsp
2 = .03, previously non-
significant).  
Table 26  
PASAT Trial 3 with and without Outliers Post Hoc 
 Model 1 Model 2 Model 3 Model 4  
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Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial correlations 
Abbreviations were also used. High Sch = High School, Cond. = Condition.  
 
PASAT Trial 4 Analysis. The full model (n = 48) for PASAT Trial 4 was 




The first predictor block including age and education produced a medium effect and was 
nonsignificant, R2 = .181, F(4, 43) = 2.376, p = .067, adjusted R2 = .105. The addition of 
condition did not produce statistically significant incremental variance, ΔF(1, 42) = 
1.278, p = .265, Δ R2= .024; however, it did produce a small effect. The third block with 
the addition of cytokines was significant and had a small effect ΔF(2, 40) = 3.237, p = 
.05, Δ R2= .111.  Finally, the addition of PTSD symptoms did not produce incremental 
variance, ΔF(1, 39) = 1.019, p = .319, Δ R2= .017.  Squared semi-partial correlations 
were interpreted within the full model. Age did not produce a meaningful effect.  Positive 
associations and a small effect were produced regarding education at the collegiate level 
(rsp
 = .323, 95% CI [.043, .556]; rsp
2 =0.10); there were  positive associations with a 
medium effect at the high school level (rsp
 = .358, 95% CI [.082, .583]; rsp
2 =0.13), and at 
the doctoral level (rsp
 = .358, 95% CI [.082, .583]; rsp
2 =0.13). The interleukin TNFα  (rsp
 
= -.294, 95% CI [-.498, .038]; rsp
2 =0.09) was negatively associated with scores with a 
small effect. INFγ and GWI were not interpreted as meaningful. However, PTSD 
symptoms showed a small effect (rsp
 = -.132 95% CI [-.401, .158]; rsp














PASAT Trial 4 Post Hoc 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2  B rsp2  B rsp2  B  rsp2  
Constant 10.8  14.76  13.39  7.75  
Age -.19 .01 -.21 .02 -.21 .02 -.1 .00 
Edu. Level         
 High School  21.76 .12 19.91 .10 21.29 .11 23.16 .13 
 Collegiate 19.1 .10 17.63 .08 19.02 .09 20.25 .10 
 Doctoral 22.73 .13 21.08 .11 22.36 .12 23.36 .13 
Condition a   -2.73 .02 -2.63 .02 .28 .00 
INFγ     -1.1 .01 -.63 .00 
TNFα     -2.42 .10 -2.31 .09 
PTSD Level b       -.05 .02 
         
R2 .181  .205  .316  .333  
R2 adj .105  .111  .196  .197  
F 2.376  2.168  2.639  2.437  
Δ R2 .181  .024  .111  .017  
Δ F 2.376  1.278  3.237  1.019  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total), c Fatigue (as designated by MFI General Fatigue); B indicates unstandardized 
coefficients, rsp2 indicates squared semi-partial correlations  
 
PASAT Trial 4 Reanalysis without Outliers. The same analysis was conducted 
without identified outliers (n = 46).  The full model on the fourth trial remained 
significant, R2 = .334, 95% CI [.161, 507], F(8, 37) = 2.319, p = .04, adjusted R2 = .190 
with a medium effect size. The addition of condition to the model was not statistically 
significant but had a small effect (Δ R2 = .023). However, the addition of cytokines was 
not significant (i.e., TNFα and INFγ) with an increase in R2 of .103, F(2, 38) = 2.861, p = 
.07 with a small effect. On the last model with the inclusion of PTSD symptoms, the 
model was significant, but PTSD did not lead to a significant increase of R(Δ R2 = .015)  
or a meaningful effect. Within the final model, the only parameters that changed were in 
the first model. There was a medium positive effect in education at the high school level 





PASAT Trial 4 Reanalysis with Recoding. Model 1 R2, Model 1 Δ R2, Model 2 
R2, had a small effect (Model 1 R2/Δ R2 = .057, Model 2 R2 = .105) which was previously 
interpreted as a medium effect size (Model 1R2/ Δ R2 = .181, Model 2 R2 = .205).  Model 
3 R2 and Model 4 R2 returned medium effect sizes (Model 3 R2 = .202, Model 4 R2 = 
.205) which previously had large effect sizes (Model 3 R2 = .316, Model 4 R2 = .333). For 
the final model semi-partial correlates, reanalysis showed differences in age (rsp
2 = .02, 
previously non-significant), high school level of education (non-significant, previously 
rsp
2 = .13), doctoral level of education (non-significant, previously rsp
2 = .13), and PTSD 
symptoms (non-significant, previously rsp
2 = .02).  
When analyzed without outliers, there were similar results in that Model 1 R2, 
Model 1 Δ R2 , and Model 2 R2 were interpreted as a small effect (Model 1 R2/Δ R2 = 
.065, Model 2 R2 = .111) which were previously a medium effect (Model 1R2/ Δ R2 = 
.193, Model 2 R2 = .216).  Model 3 R2 and Model 4 R2 revealed a medium effect (Model 
3 R2 = .202, Model 4 R2 = .205) from a previously large effect size (Model 3 R2 = .319, 
Model 4 R2 = .334).  For the final model semi-partial correlates, reanalysis showed 
differences in age (rsp
2 = .02, previously non-significant),  high school level of education 
(non-significant, previously rsp
2 = .13), doctoral level of education (non-significant, 
previously rsp
2 = .13), and PTSD symptoms (non-significant, previously rsp











PASAT Trial 4 with and without Outliers Post Hoc 
  
 Model 1 Model 2 Model 3 Model 4  
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Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial correlations 
Abbreviations were also used. High Sch = High School, Cond. = Condition.  
 
PASAT Results by Condition, TNFα/INFγ/IL-6/IL-8, and PTSD Symptoms  
Another hierarchical regression model was utilized to investigate if condition 
(GWI status), cytokines (i.e., TNFα, INFγ, IL-6, and IL-8), and PTSD symptoms would 
predict how veterans performed on a measure of working memory and attention 




across models: Block 1 (Age and Education), Block 2(GWI), Block 3 (TNFα,  INFγ, IL-
6, and IL-8) and Block 4 (PTSD symptoms). Tables 29 through 36 present selected 
statistical information from the analyses.  
PASAT Trial 1. Regression models were used on available data (n = 44) to test if 
GWI status, TNFα, INFγ, IL-6, and IL-8 and PTSD symptoms had an impact on attention 
and working memory. The full model for PASAT Trial 1 was nonsignificant, R2 = .279, 
95% CI [.121, .437], F(10, 33) = 1.277, p = .283, adjusted R2 = .06. The first predictor 
block including age and education returned a medium effect, R2 = .161, F(4, 39) = 1.877, 
p = .134, adjusted R2 = .075. The addition of health condition did not contribute 
significantly by means of incremental variance, ΔF(1, 38) = .281, p = .599, Δ R2= .006. 
The addition of cytokines did not produce significant incremental variance but had a 
small effect, ΔF(4, 34) = 1.311, p = .286, Δ R2= .279. Finally, the addition of PTSD 
symptoms did not add incremental variance, ΔF(1, 33) = .006, p = .937, Δ R2= .00. In the 
final model, squared semi-partial correlations showed a negative association and small 
effect with age (rsp
 = -.220, 95% CI [-.485, .082]; rsp
2 =0.05). Positive associations and a 
small effect were produced regarding education at the high school level (rsp
 = .166, 95% 
CI [ -.138, .441]; rsp
2 =0.03), collegiate level (rsp
 = .159, 95% CI [-.145, .435]; rsp
2 =0.03),  
and the doctoral level (rsp
 = .247, 95% CI [=-.054, .507]; rsp
2 =0.06). Furthermore, some 
cytokines also demonstrated a small effect size including INFγ (rsp
 = -.163, 95% CI [-
.439, .141]; rsp
2 =0.03) and TNFα  (rsp
 = -.194, 95% CI [ -.464, .109]; rsp
2 =0.04). The 







PASAT Trial 1 Added Cytokines 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2  B rsp2  B rsp2  B  rsp2  
Constant 48.03  51.4  47.7  48.46  
Age -.6 .06 -.62 .06 -.61 .06 -.62 .05 
Edu. Level         
 High School  15.23 .03 13.77 .02 16.54 .03 16.32 .03 
 Collegiate 13.22 .02 12.03 .02 15.23 .03 15.04 .03 
 Doctoral 22.82 .06 21.25 .05 24.7 .06 24.64 .06 
Condition a   -2.18 .01 -1.62 .00 -2.04 .00 
INFγ     -4.27 .03 -4.32 .03 
TNFα     -3.08 .04 -3.08 .04 
IL-6     1.14 .01 1.15 .01 
IL-8     -1.08 .00 -1.13 .00 
PTSD Level b       .007 .00 
         
R2 .161  .168  .279  .279  
R2 adj .075  .058  .088  .060  
F 1.877  1.530  1.461  1.277  
Δ R2 .161  .006  .111  .000  
Δ F 1.877  .281  1.311  .006  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial 
correlations  
 
PASAT Trial 1 Reanalysis without Outliers. Assumption testing of the data 
revealed two potential outliers which were excluded for the following analysis (n = 43). 
The analysis interpretation did not change with the full model for PASAT 1 as it 
remained nonsignificant (see Table 30 for comparison values). Additionally, model and 
squared semi-partial correlation effect sizes did not produce a notable change in values 
and were interpreted in the same manner. 
PASAT Trial 1 Reanalysis with Recoding. PASAT data was reanalyzed to 
include the participant with elementary level education (n =1) by combining his data with 
other participants with a high school education. In terms of R2 effect size, Model 3 and 
Model 4 showed a difference as it was medium (Model 3: .249, Model 4: .251) whereas it 
was previously large (Model 3: .279, Model 4: .279). In terms of semi-partial correlation 




and previously produced small effect sizes (Model 1: .03, Model 2: .02, Model 3: .03, 
Model 4: .03) . 
When analyzed without outliers,  there were similar results in that the R2 effect 
size was medium (Model 3: .248, Model 4: .251) instead of large (Model 3: .278, Model 
4: .27) and the semi-partial  correlation effect size in the full model showed that high 























PASAT Trial 1 Added Cytokines with and without Outliers  
  
 Model 1 Model 2 Model 3 Model 4  













































































































































































Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial correlations 
Abbreviations were also used. High Sch = High School, Cond. = Condition.  
 
PASAT Trial 2. The full model (n = 44) for PASAT Trial 2 was nonsignificant, 
R2 = .317, 95% CI[.157, .477], F(10, 33) = 1.532, p = .172, adjusted R2 = .110. The first 
predictor block (age and education) demonstrated a medium effect but was 




block (health condition) did not return significant incremental variance, ΔF(1, 38) = 
1.218, p = .277, Δ R2= .027; however, there was a small effect. Next, Block 3 with the 
addition of cytokines showed a medium effect but was also nonsignificant, ΔF(4, 34) = 
1.822, p = .146, Δ R2= .146.  Finally, the addition of PTSD symptoms did not produce 
incremental variance, ΔF(1, 33) = .024, p = .877, Δ R2= .001. In the final model, squared 
semi-partial correlations revealed a negative association and small effect in age (rsp
 = -
.172, 95% CI [-.446, .132]; rsp
2 =0.03). Positive associations and a small effect were 
produced regarding education at the high school level (rsp
 = .125, 95% CI [-.179, .407]; 
rsp
2 =0.02), and doctoral level (rsp
 = .225, 95% CI [-.077, .489]; rsp
2 =0.05). All other 
levels of education did not indicate a meaningful effect. The cytokines showed a negative 
association with a small effect size in INFγ (rsp
 = -.127, 95% CI [-.408, .177]; rsp
2 =0.02),  
TNFα  (rsp
 = -.148, 95% CI [-.426, .156]; rsp
2 =0.02) and IL-8(rsp
 = -.158, 95% CI [-.434, 
.146]; rsp















PASAT Trial 2 Added Cytokines 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2  B rsp2  B rsp2  B  rsp2  
Constant 41.69  47.91  43.64  44.93  
Age -.38 .03 -.42 .04 -.41 .04 -.44 .03 
Edu. Level         
 High School  9.97 .01 7.27 .01 11.25 .02 10.87 .02 
 Collegiate 8 .01 5.8 .01 9.23 .01 8.92 .01 
 Doctoral 18.81 .05 15.92 .03 20.04 .05 19.94 .05 
Condition a   -4.01 .03 -2.66 .01 -3.38 .01 
INFγ     -2.89 .02 -3 .02 
TNFα     -2.08 .02 -2.08 .02 
IL-6     .726 .01 .75 .01 
IL-8     -2.45 .03 -2.54 .03 
PTSD Level b       .01 .00 
         
R2 .143  .170  .317  .317  
R2 adj .056  .061  .136  .110  
F 1.633  1.557  1.75  1.532  
Δ R2 .143  .027  .146  .001  
Δ F 1.633  1.218  1.822  .024  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial 
correlations  
 
PASAT Trial 2 Reanalysis without Outliers. The analysis interpretation did not 
change with the full model for PASAT 2 as it remained nonsignificant (see Table 32). 
Additionally, model effect sizes did not produce a notable change in values and were 
interpreted in the same manner. However, the semi-partial correlation effect size for 
TNFα was non-meaningful whereas it was previously a small effect (.02). 
PASAT Trial 2 Reanalysis with Recoding. PASAT data reanalysis showed no 
difference in significance or effect sizes in data without outliers. When analyzed without 
outliers, analysis change in that the semi-partial squared effect size showed a difference 
in high school which was previously a small effect (.02) and now non-meaningful. 
Additionally, the effect size for condition in both Model 3 and Model 4 showed a small 






PASAT Trial 2 Added Cytokines with and without Outliers 
  
 Model 1 Model 2 Model 3 Model 4  













































































































































































Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial correlations 
Abbreviations were also used. High Sch = High School, Cond. = Condition.  
 
PASAT Trial 3 Analysis. The full model (n = 44) for PASAT Trial 3 was 
nonsignificant, R2 = .323, 95% CI [.163, .483], F(10, 33) = 1.572, p = .159, adjusted R2 = 
.117. The first predictor block (i.e., age and education) returned a medium effect but was 
also nonsignificant, R2 = .156, F(4, 39) = 1.805, p = .147, adjusted R2 = .070. The second 




38) = 1.386, p = .246, Δ R2= .030, but produced a small effect. The third predictor block 
(i.e., cytokines) was noncontributory to incremental variance but produced a medium 
effect ΔF(4, 34) = 1.668, p = .180, Δ R2= .134.  Finally, the fourth predictor block (i.e., 
PTSD symptoms) did not produce incremental variance, ΔF(1, 33) = .156, p = .695, Δ 
R2= .003.  Squared semi-partial correlations were interpreted for the full model. Age was 
negatively associated with scores and had a small effect (rsp
 = -.73, 95% CI [-.844, -.553]; 
rsp
2 =0.03). Positive associations and a small effect were produced regarding education at 
the high school level (rsp
 = .226, 95% CI [-.076, .490]; rsp
2 =0.05), at the collegiate level 
(rsp
 = .198, 95% CI [-.105, .467]; rsp
2 =0.04), and at the doctoral level (rsp
 = .25, 95% CI     
[-.051, .509]; rsp
2 =0.06). The correlation for health condition also had a small effect, (rsp
 
= -.146, 95% CI [-.424, .158]; rsp
2 =0.02). The cytokines were in the negative direction 
and demonstrated small effect sizes, INFγ (rsp
 = -.184, 95% CI [-.456, .119]; rsp
2 =0.03), 
and TNFα  (rsp
 = -.265, 95% CI [-.521, .035]; rsp
2 =0.07). Interleukins IL-6 and IL-8 as 














PASAT Trial 3 Added Cytokines 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2  B rsp2  B rsp2  B  rsp2  
Constant 26.48  32.14  29.82  32.63  
Age -.29 .02 -.33 .03 -.32 .03 -.38 .03 
Edu. Level         
 High School  18.72 .07 16.27 .05 17.79 .06 16.97 .05 
 Collegiate 14.6 .04 12.61 .03 15.00 .04 14.32 .04 
 Doctoral 19.88 .07 17.25 .05 19.32 .06 19.10 .06 
Condition a   -3.65 .03 -3.61 .02 -5.17 .02 
INFγ     -3.54 .03 -3.74 .03 
TNFα     -3.21 .07 -3.21 .07 
IL-6     .622 .01 .683 .01 
IL-8     .173 .00 -.016 .00 
PTSD Level b       .026 .00 
         
R2 .156  .186  .319  .323  
R2 adj .070  .079  .139  .117  
F 1.805  1.735  1.773  1.572  
Δ R2 .156  .030  .134  .003  
Δ F 1.81  1.386  1.668  .156  
Note. *p < .05, **p <.001,a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total), c Fatigue (as designated by MFI General Fatigue); B indicates unstandardized 
coefficients, β indicates standardized coefficients, rsp2 indicates squared semi-partial correlations  
 
PASAT Trial 3 Reanalysis without Outliers. The analysis interpretation did not 
change with the full model as it was nonsignificant (see Table 34). Additionally, model 
and squared semi-partial correlation effect sizes did not return a notable change. 
PASAT Trial 3 Reanalysis with Recoding. The reanalysis of the PASAT data 
with outliers showed no difference in significance. In regard to model effect sizes, the 
first model showed a small effect size (.087) which was previously a medium effect size 
(.156). Semi-partial correlation effect sizes for the full model also showed that high 
school was now non-meaningful (previously a small effect = .05), that TNFα was non-
meaningful and previously a small effect =.07)., and that IL-8 had a small effect (.02) 
which was previously non-meaningful. Analysis of the data without outliers also showed 
that the first model was now a small effect (R2 =.084) which was previously non-




changes in high school educational level (non-significant, previously rsp
2 = .05). 
Table 34 
PASAT Trial 3 Added Cytokines with and without Outliers 
  
 Model 1 Model 2 Model 3 Model 4  













































































































































































Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial correlations 
Abbreviations were also used. High Sch = High School, Cond. = Condition.  
 
PASAT Trial 4 Analysis. The full model (n = 44) for PASAT Trial 4 was 
nonsignificant, R2 = .351, 95% CI [.191, .511], F(10, 33) = 1.783, p = .103, adjusted R2 = 
.154. The first predictor block including age and education produced a medium effect and 




condition did not produce statistically significant incremental variance, ΔF(1, 38) = 
1.384, p = .247, Δ R2= .028; however, it did produce a small effect. The third block with 
the addition of cytokines was nonsignificant and had a small effect ΔF(4, 34) = 1.384, p = 
.260, Δ R2= .106.  Finally, the addition of PTSD symptoms did not produce incremental 
variance, ΔF(1, 33) = .068, p = .796, Δ R2= .001.  Squared semi-partial correlations were 
interpreted within the full model. Age did not produce a meaningful effect.  Positive 
associations and a small effect were produced regarding education at the collegiate level 
(rsp
 = .308, 95% CI [.012, .554]; rsp
2 =0.10); there were  positive associations with a 
medium effect at the high school level (rsp
 = .346, 95% CI [.055, .583]; rsp
2 =0.12), and at 
the doctoral level (rsp
 = .365, 95% CI [.076, .597]; rsp
2 =0.13). The interleukin TNFα  (rsp
 
= -.211, 95% CI [-.092, .478]; rsp
2 =0.04) was negatively associated with scores with a 
















PASAT Trial 4 Added Cytokines 
  
 Model 1 Model 2 Model 3 Model 4  
Variable B rsp2  B rsp2  B rsp2  B  rsp2  
Constant 9.44  14.1  12.38  10.83  
Age -.16 .01 -.19 .01 -.19 .01 -.15 .01 
Edu. Level         
 High School  22.28 .13 20.21 .11 21.73 .12 22.18 .12 
 Collegiate 18.57 .10 16.92 .08 18.67 .09 19.05 .10 
 Doctoral 24.29 .15 22.13 .12 23.71 .13 23.83 .13 
Condition a   -3.01 .03 -2.74 .02 -1.87 .00 
INFγ     -1.53 .01 -1.42 .01 
TNFα     -2.19 .05 -2.19 .05 
IL-6     .08 .00 .04 .00 
IL-8     -.22 .00 -.12 .00 
PTSD Level b       -.01 .00 
         
R2 .216  .243  .349  .351  
R2 adj .1366  .144  .177  .154  
F 2.69*  2.45*  2.03  1.78  
Δ R2 .216*  .028  .106  .001  
Δ F 2.69*  1.38  1.38  .068  
Note. *p < .05, **p <.001, a Case designation (GWI or Healthy Control), b PTSD level (PTSD-related 
symptoms from DTS total), c Fatigue (as designated by MFI General Fatigue); B indicates unstandardized 
coefficients, rsp2 indicates squared semi-partial correlations  
 
PASAT Trial 4 Reanalysis without Outliers. The analysis interpretation did not 
change with the full model for PASAT 4 as it remained significant (see Table 36). 
Additionally, model effect sizes did not produce a notable change in values and were 
interpreted in the same manner. However, the semi-partial correlation effect size for age 
in Model 2 had a small effect (.02), when it was previously non-meaningful.  
PASAT Trial 4 Reanalysis with Recoding. There was a change in statistical 
significance as Model 1 and Model 2 were now non-significant, which previously had a p 
value at or below .05. Model 1 R2, Model 1 Δ R2 had a small effect (Model 1 R2/Δ R2 = 
.082) which was previously interpreted as a medium effect size (Model 1R2/ Δ R2 = .216).  
Model 3 R2 and Model 4 R2 returned medium effect sizes (Model 3 R2 = .230, Model 4 
R2 = .231) which previously had a large effect sizes (Model 3 R2 = .349,  Model 4 R2 = 




school level of education (non-significant, previously rsp
2 = .12), doctoral level of 
education (small effect = .03, previously rsp
2 = .13), and health condition (small effect = 
.03, previously non-meaningful).  
When analyzed without outliers, there were similar results in that Model 1 R2, and 
Model 1 Δ R2 were interpreted as a small effect (Model 1 R2/Δ R2 = .089) which were 
previously a medium effect (Model 1R2/ Δ R2 = 225).  Model 3 R2 and Model 4 R2 
revealed a medium effect (Model 3 R2 = .23, Model 4 R2 = .23) from a previously large 
effect size (Model 3 R2 = .349, Model 4 R2 = .35).  For the final model semi-partial 
correlates, reanalysis showed differences in age (rsp
2 = .03, previously non-significant),  
high school level of education (non-significant, previously rsp
2 = .12), doctoral level of 
education (small effect = .03, previously rsp
2 = .13), and health condition  (rsp
2 = .03, 

















PASAT Trial 4 Added Cytokines with and without Outliers  
  
 Model 1 Model 2 Model 3 Model 4  













































































































































































Note. *p < .05, **p <.001, Analysis without outliers within parentheses, a Case designation (GWI or Healthy 
Control), b PTSD level (PTSD-related symptoms from DTS total), c Fatigue (as designated by MFI General 
Fatigue); B indicates unstandardized coefficients, rsp2 indicates squared semi-partial correlations 










Figure 8. The change in R2 across all four PASAT trials for GWI, Cytokines and Trauma (PTSD). This 
graph shows that cytokines had the highest effect across trials. GWI also had a meaningful effect in Trial 2, 
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Figure 9. Coefficient effect size as plotted by each trial for Model 1 which included age and education level 
(high school, college, doctorate). Age showed a meaningful effect until Trial 4. For education, a doctoral 
level of education demonstrated a meaningful effect across all trials. A high school level of education 
showed a meaningful effect for all trials except Trial 2. A collegiate level of education was only 
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Figure 10. Coefficient effect size as plotted by each trial for Model 2 which included age, education level 
(high school, college, doctorate), and health condition (GWI or healthy control). Age and education levels 
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Model 2 Effect Sizes Age, Education, and GWI





Figure 11. Coefficient effect size as plotted by each trial for Model 3 which included age, education level 
(high school, college, doctorate), health condition (GWI or healthy control), and cytokines INFγ and TNFα. 
Age and doctoral level of education retained the same pattern. The high school level of education showed 
meaningful impacts on Trial 1, 3, 4 in addition to a collegiate level of education. GWI was only meaningful 
in the last PASAT trial. One of the stronger predictors was TNFα which was meaningful across trials. 
However, INFγ showed a different pattern as it decreased in effect size with a non-meaningful effect in the 





















PASAT 1 PASAT 2 PASAT 3 PASAT 4
Model 3 Effect Sizes Age, Education, GWI, and Interleukins





Figure 12. Coefficient effect size as plotted by each trial for Model 4 which included age, education level 
(high school, college, doctorate), health condition (GWI or healthy control), cytokines INFγ and  TNFα, 
and PTSD level. Age and education level retained the same pattern as Model 3. GWI did not demonstrate a 
meaningful effect. TNFα remained a strong predictor across trials. Additionally, INFγ was significant 























PASAT 1 PASAT 2 PASAT 3 PASAT 4
Full Model Effect Sizes Age, Education, GWI, Interleukins, 
and PTSD




Chapter V: Discussion  
            The present study was designed to investigate GWI, a debilitating and poorly 
understood condition, and its impact on cognition, a common symptom endorsed by 
diagnosed veterans (Smith et al., 2012; Yee et. al., 2016).  Research investigating GWI is 
limited; as such, research investigating neuropsychological performance in GWI is 
understandably sparse, especially when considering how aspects such as trauma and 
fatigue, may also confound the relationship between GWI and cognitive functioning. 
Initially, this study had two primary goals. The first goal was to investigate the unique 
contribution of GWI, PTSD symptoms, and fatigue towards performance across four 
trials of a measure of working memory and attention while controlling for age and 
education level. Secondly, the investigator aimed to analyze how GWI and levels of 
targeted interleukins, IL-4 and IL-10, impacted reported levels of fatigue across five 
domains: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Activity, and 
Reduced Motivation. Given the lack of meaningful results within the second analysis, the 
researcher tested a post-hoc hypothesis that investigated how GWI, pro-inflammatory 
cytokines correlated with PASAT, and PTSD symptoms contributed to performance on 
the attention and working memory measure while controlling for age and educational 
level. All of these hypotheses were tested with a set of hierarchical regression analyses, 
detailed further.  
Primary Outcomes  
            The first goal of this current study was to examine how GWI, PTSD, and fatigue 
impacted the amount of correct answers on a measure of working memory and attention 




variance (after accounting for age and education) followed by PTSD symptoms and 
fatigue. Therefore, GWI status would overall be the primary factor that contributed to 
worse scores on the PASAT, with trauma being the second most relevant factor followed 
by fatigue. 
            Primary Outcome First Hypothesis. Regarding demographic factors, the GWI 
and healthy control group did not differ significantly on age or educational demographic 
factors. Additionally, the GWI and healthy control group were roughly consistent 
regarding the dispersion of different age ranges, race, ethnicity, and educational levels. 
Analysis of the full model (Model 4) with age and education, GWI status, PTSD 
symptoms, and fatigue did not return any statistical significance as defined by an alpha 
level at or below .05. Additionally, no hierarchical models prior to the full model (Model 
1, Model 2, and Model 3) demonstrated statistical significance. These results are likely 
attributable to the underpowered sample size; therefore, effect sizes for the overall 
models and coefficients were calculated to estimate a clinical effect. For the first trial of 
PASAT, the only model that showed a meaningful effect (R2  = .178) was the first model 
with age and education, showing that increase in age was generally associated with 
poorer scores on the PASAT and education overall was associated with higher scores. 
The second trial of PASAT, with a slight increase in task demands, again showed that the 
model with age and education was the only model that met the threshold of clinical 
significance (R2  = .136) with age associated with worse scores and education (i.e., high 
school and doctorate) associated with higher scores. However, the second model 
approached a meaningful effect (ΔR2 = .019) with GWI status associated with poorer 




third trial of the PASAT, only age and education remained significant predictors, 
demonstrating the same trends as previous trials in Model 1 (R2  = .161). The most 
interesting findings were seen in the last trial of the PASAT, Trial 4, which is the most 
difficult trial with the highest task demands. The first model demonstrated a meaningful 
effect (R2  = .184).; however, education accounted for the meaningful variance, with age 
no longer associated with score performance. The second model, which added GWI, 
demonstrated an effect approaching a meaningful score (ΔR2 = .019), with GWI 
demonstrating a small effect and negatively impacting scores. However, the third model 
was clinically significant (ΔR2 = .034) and GWI as a predictor was no longer meaningful 
once PTSD symptoms were added to the model.  
Therefore, these results did not support the hypothesis that GWI status would 
account for the most variance once controlling for age and education. At best, when GWI 
is added to the model, it approaches significance and parameters show a possible small 
effect size. However, the only other model that met the threshold outside of age and 
education models included GWI and PTSD with PTSD accounting for the meaningful 
variance. Therefore, GWI may only be somewhat meaningful when psychological 
variables are not accounted for via the analyses.  
Of note, these analyses were performed again without identified outliers. The 
interpretation of the data virtually remained the same with a few exceptions.  Within the 
PASAT Trial 3, the second model approached significance, but did not meet the 
threshold, indicating a possible small effect associated with a GWI diagnosis. 
Additionally, in the fourth trial of the PASAT, the first model with age and education met 




remained the same with PTSD accounting for more variance over GWI once added to the 
model.  
The PASAT data was also reanalyzed using recoded education data in which the 
elementary school participant (n = 1) was included in the high school level education 
group. The interpretation of the data with outliers changed as high school level of 
education now had a non-meaningful semi-partial correlation effect size in the final 
model of PASAT Trial 1. Additionally, PASAT Trial 2 results were interpreted 
differently as the R2 effect size showed a small effect in Model 1 (.12) and Model 2 
(.026). PASAT Trial 3 returned different scores as the R2 effect size in Model 1 (.086), 
Model 2 (.116), Model 3 (.116) and Model 4 (.124) was interpreted as small. 
Furthermore, the incremental R2 effect size for Model 2 was now a small effect size (.03). 
Lastly, for semi-partial correlation effect sizes of the final model, age had a small effect 
whereas high school and doctoral level of education was now non-meaningful. Finally, 
PASAT Trial 4 returned different R2 effect sizes for Model 1 (.051), Model 2 (.1), Model 
3 (.11) and Model 4 (.11) which were interpreted as small effect sizes. As in Trial 3, the 
incremental R2 effect size for Model 2 was now a small effect (.05). Lastly, the semi-
partial correlations did not return a meaningful effect for high school education, doctoral 
education, or PTSD symptoms.  
These results are inconsistent with the more rigorous literature regarding GWI 
and neuropsychological problems, pointing towards a problem in attention (Januelwicz et 
al., 2017; Sullivan et al., 2018) in those with GWI. However, these studies included 
multiple measures of attention; therefore, these results may differ based on the limitation 




(David et al., 2002; Toomey et al., 2009; Wallin et al., 2009; White et al., 2001) did not 
find significant or effect sizes that were meaningful (Wallin et al., 2009) once accounting 
for multiple comparisons (White et al., 2001). Additionally, some studies found 
significance, but once psychological effects were accounted for, the relationship was no 
longer significant (Lange et al., 2001; Lindem et al., 2003). Therefore, the PASAT may 
be measurement that is sensitive to psychological issues, making it difficult to partial out 
biological correlates of poor attention in GWI. 
Primary Outcome Second Hypothesis. The secondary aim of this investigation 
was to test if health condition and interleukins were linked to the fatigue factor, 
anticipating that fatigue was also a significant contributor to poor cognitive outcomes. 
Although fatigue was not a significant factor for the PASAT, analysis on all five domains 
of the MFI (i.e., General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Fatigue, and 
Reduced Activity were carried out. The first variable tested was health condition, GWI 
versus healthy controls, followed by interleukins. Interleukins were identified via 
previous research as IL-4 and IL-10 were associated with MFI results (Broderick et al., 
2013). Results across all five domains showed a major effect in health condition. 
Veterans diagnosed with GWI were more likely than their healthy counterparts to endorse 
higher levels of General Fatigue (R2 = .582, p < .001), Physical Fatigue (R2 = .562, p < 
.001), Mental Fatigue (R2 = .503, p < .001), Reduced Activity (R2 = .489, p < .001), and 
Reduced Motivation (R2 = .489, p < .001). The addition of interleukins overall did not 
significantly add to the model outside of a small effect of IL-4 that pointed towards 
higher levels of this interleukin begin associated with higher levels of Mental Fatigue.  




outliers, interleukins initially showed a small meaningful effect, ΔR2= .049; however, IL-
4 and IL-10 alone did not produce meaningful results. However, Physical Health showed 
a small meaningful effect in the interleukin module, with IL-10 elevations being 
associated with higher levels of Physical Fatigue. Overall, the only difference in 
interpretation was the possible association between higher IL-10 and higher levels of 
Physical Fatigue.    
The finding that Mental Fatigue (i.e., poor concentration, difficulty focusing) was 
associated with IL-4 is unique. The relationship underlying this connection remains 
unclear as IL-4 is not as well studied as other cytokines in relation to psychological 
variables. IL-4 is known to be involved in a Th2 immune response (anti-inflammatory 
responses). However, IL-4 is also associated with allergies, autoimmunity, and cancer 
(Craddock et al., 2015). In regard to GWI, IL-4 has been elevated in veterans deployed to 
the Gulf War and may have an impact on immune activation (Skowera et al., 2004). 
Additionally, IL-4 has been elevated in chronic fatigue syndrome, indicating a possible 
etiology (Montoya et al., 2017; Fletcher et al., 2009). However, it remains unclear how 
IL-4 contributes to mentally based fatigue, and no precedent has been established in 
literature linking higher levels of IL-4 to issues with poor concentration and focus. 
However, researchers have hypothesized that pro-inflammatory cytokines as well as 
cytokine imbalance has a role in mood disorders including ADHD. One study 
demonstrated that children with comorbid ADHD and asthma (i.e., a disorder associated 
with IL-4 levels) had higher risk of developing a major depressive disorder or a bipolar 
disorder (Chen et al., 2013). Additionally, cerebral spinal fluid analysis of ADHD 




2014). However, another study investigating early-onset schizophrenia demonstrated that 
higher levels of IL-4 were associated with the negative symptoms of schizophrenia, 
known to be associated with more cognitive deficits. Therefore, the literature remains 
unclear about the specific role IL-4 has in cognitive behavior, which is understandable 
given the complexity of the issues as well as the sensitivity to the immune systems in 
shifts in interleukins (Simsek et al., 2016).  
The association between elevated IL-10 and elevated Physical Fatigue has minor 
support in research literature. Some studies support this possible finding as IL-10 has 
been elevated in those with chronic fatigue syndrome, a “sister” diagnosis to GWI as it 
also is characterized by fatigue levels (Brenu et al., 2011, Nakamura et al., 2010, 
Natelson et al., 2005). A systematic literature review investigating CFS and immune 
levels showed that interleukin-10 genetic expression was also significantly higher and 
associated to post-exertional malaise (Nijs et al., 2014). However, it is unclear how IL-10 
is specific to fatigue in a physical sense outside of this current finding.  
Primary Outcome Post-Hoc Analysis. The PASAT data model was re-analyzed, 
removing fatigue as a variable, as fatigue measures did not contribute significantly, and 
the literature did not support the use of the PASAT in fatigue-like syndromes (Johnson et 
al. 1997). Additionally, pro-inflammatory cytokines correlated with the PASAT were 
added to investigate an immunological trend in attention and working memory. Analysis 
was conducted through a hierarchical regression model with the first model controlling 
for age and education, the second model adding health condition (GWI versus healthy 
controls), the third model adding notable proinflammatory cytokines (i.e., TNFα and 




variables only showed significance within the last trial of the PASAT, with the last added 
variable of PTSD not demonstrating a significant change. Therefore, effect sizes were 
used to determine meaningful significance given that the sample size likely contributed to 
reduced power. Lastly, the investigator was primary interested in the original data; 
therefore, the difference in results based on the absence of outliers or recoded education 
data is detailed in Tables 22, 24, 26, and 28 and specified results section. 
Effects sizes, as determined by Δ R2 was used to determine if added variables 
contributed meaningfully to the model after controlling for age and education. The most 
striking finding across the models was that the addition of cytokines overall contributed 
to significant change in all four trials of the PASAT (Trial 1 Δ R2 = .085; Trial 2 Δ R2 = 
.108; Trial 3 Δ R2 = .120; Trial 4 Δ R2 = .111). Additionally, cytokines appeared to play 
more of a role in PASAT performance in harder trials (i.e., Trial 3 and 4). Health 
condition, or GWI status, which was hypothesized to be the most significant contributor 
appeared to have a small impact on PASAT Trials 2 through 4 (Trial 1 Δ R2 = .008; Trial 
2 Δ R2 = .027; Trial 3 Δ R2 = .025; Trial 4 Δ R2 = .024). However, PTSD symptoms did 
not contribute meaningfully to any PASAT trials.  
To investigate specific contributions, overall effect sizes in conjunction with 
coefficient effect sizes were also investigated for each PASAT trial. For the first PASAT 
trial, the first model that included only age and education demonstrated a meaningful 
effect (R2 = 164) with age negatively associated with PASAT performance and education 
positively associated with PASAT performance. The only other model with a meaningful 
effect for the first trial was Model 3 with age, education, GWI status, and cytokines (Δ R2 




indicating that higher levels of these pro-inflammatory cytokines were indicative of 
worse performance on the first trial of the PASAT.  
Analyses of the second PASAT trial, showed that Model 1 with age and 
education, Model 2 with age, education, and health status, and Model 3 with age, 
education, health status, and cytokines demonstrated a meaningful effect. As stipulated 
before, increased age was linked to worse PASAT performance; however, only education 
at the doctoral level was associated with higher scores. Model 2 had the same results in 
regard to age and education level; however, those with GWI were more likely to perform 
worse on the second trial of the PASAT. With the addition of the cytokines, age, 
education, and GWI status demonstrated the same patterns. Both TNFα and INFγ 
continued to have a small and negative impact on PASAT Trial 2 performance.  
For the third PASAT trial, an overall meaningful effect was also seen in Model 1, 
Model 2, and Model 3. However, Model 3 was also statistically significant, with 
cytokines leading to a Δ R2 of .120, Δ F (2, 40) = 3.391, p = .044, and an overall model 
significance of F(7, 40) = 2.349, p = .042. For Model 1, the age coefficient had a small 
negative impact on PASAT scores while all education level coefficients demonstrated a 
positive impact. For Model 2, age and education coefficients held the same effect while 
GWI contributed negatively to PASAT scores on a small scale. For Model 3, the 
coefficients for age, education, and GWI continued to demonstrate the same pattern; 
however, the addition of both TNFα and INFγ showed a small and negative impact on 
PASAT performance.  
For the last and hardest PASAT Trial, Model 1, 2, and 3 demonstrated a 




continued to be associated with higher PASAT Trial 4 scores. Of note, doctoral education 
had a medium level impact while high school and college levels had a small impact. For 
Model 2, age was shown to have a small negative impact, whereas all education levels 
had a small positive impact on PASAT scores. GWI, as an added variable, showed a 
small negative impact as well. For Model 3, there was statistical significance alongside a 
meaningful effect for the addition of cytokines with a Δ R2 of .111, Δ F (2, 40) = 3.391, p 
= .05, and an overall model significance of F(7, 40) = 2.639, p = .024. All other 
coefficients (i.e., age, education, and GWI) retained the direction and level of impact on 
the PASAT. However, only TNFα showed a meaningful effect. Of note, the last model 
did have overall statistical significance even though the effect was not interpreted as 
meaningful (Δ R2 = .017). Nevertheless, when investigating the individual coefficients, 
PTSD showed a small meaningful effect. Additionally, age and GWI no longer had a 
negative impact on scores. Education levels ranged from small to medium and 
contributed to higher PASAT scores. TNFα and INFy showed a meaningful effect. 
Given these results, GWI status had a small but meaningful effect particularly 
with later trials of the PASAT. Therefore, the post-hoc analysis somewhat supports the 
hypothesis that GWI status contributes to performance on a test of working memory and 
attention; however, these results are interpreted very conservatively given it was 
conducted as a post-hoc analysis. These results are more in line with literature pointing 
towards issues with attention in individuals with GWI (Januelwicz et al., 2017; Sullivan 
et al., 2018). Additionally, as the PASAT is a challenging task with further demands with 
each subsequent trial, the contribution of GWI within Trial 2, 3, and 4 follow patterns in 




under a challenge (Broderick et al., 2011). Additionally, GWI status remained significant 
within the later trials even with the addition of PTSD in the model demonstrating that this 
pattern may not be solely attributable to issues related to psychological distress. 
However, GWI was not the most significant contributor the model, revealing the 
difficulty in diagnosing GWI given its multifactorial and heterogenous nature in regard to 
symptom expression. Therefore, the role of cytokines, or a more objective measure of 
immunological dysfunction, was investigated and found to be more meaningful.  
Based on these results, there is tentative evidence that cytokines TNFα and INFγ 
may point towards an underlying process of poorer performance in sustained attention 
and working memory. Considering GWI, irregular levels of TNFα have been observed in 
GWI veterans more often than not across investigations. Multiple studies have shown that 
there is suppressed activity of TNF receptors and higher responsiveness in those with 
GWI (Broderick et al., 2011; Broderick et al., 2013; Khaiboullina et al., 2015; Whistler et 
al., 2009). However, Everson et al. (2002) did not find differences in TNFα  when 
comparing those veterans who were healthy with veterans that were symptomatic. 
Differences in these studies may be attributed to methodological differences as Everson 
et al. (2002) did not investigate GWI as defined by Fukuda et al. (1998) and tested levels 
of cytokine at rest. The aforementioned studies had a clear definition of GWI and also the 
majority of studies investigated cytokines levels at various timepoints (i.e., at rest, 
exertion). Regarding PTSD, there are inconsistent results regarding TNFα levels and 
associated PTSD symptoms. Himmerich et al. (2016) found that treatment of PTSD was 
associated with increased production of TNFα. However, the majority of studies, as 




higher PTSD symptoms (Passos et al., 2015). Regarding the cognitive impact of TNFα, 
there is evidence that higher levels of TNFα in the hippocampus may impact long-term 
potentiation which impacts the ability to learn and remember information (Belarbi et al., 
2012; McAfoose & Baune, 2008). Therefore, increased levels may have an impact on an 
individual’s ability to use their working memory to learn and retain numbers.  
Given that interleukin levels did not change when PTSD was added to the model, 
it appears that GWI may be more linked to TNFα, which remained a meaningful effect 
for the PASAT overall. However, this is a tentative interpretation as the cause of the 
interleukin’s change (i.e. GWI or PTSD) was investigated via trends over group 
differences which would more clearly differentiate patterns. 
In regard to INFγ, studies point towards higher levels in GWI. Elevated INFγ has 
been associated with veterans with multisymptom illness in vitro after controlling for age, 
sex, and vaccination status (Skowera et al., 2004) as well as in GWI subjects overall 
(Khaiboullina et al., 2015). In studies with an exercise paradigm, higher levels of INFγ in 
GWI cases has been associated with higher stimulation during the exercise challenge 
(Broderick et al., 2011) in addition to all time points (Whistler et al., 2009; Smylie et al., 
2013). In regard to PTSD, metanalysis supported that PTSD symptoms were also 
associated with higher levels of INFγ in comparison to healthy controls. Furthermore, this 
pattern indicates a shift towards Th1 or a proinflammatory response given the higher 
levels of INFγ (Zhou et al., 2014). Unfortunately, there has not been extensive research 
investigating potential issues with working memory or attention and differing INFγ 
levels. However, higher levels of INFγ have been observed in patients with ADHD 




of attention and working memory.  
The final analysis was conducted to include IL-6 and IL-8 in the same model for 
the post hoc analysis. Therefore, the  hierarchical regression model was designed to have 
the first model with predictors of  age and education, the second model with the health 
condition predictor, the third model with the TNFα, INFγ, IL-6, and IL-8 predictors , and 
the fourth model with the PTSD symptoms predictors. Given the similarity of the models, 
the primary focus of the discussion will be on the added interleukins or changes in the 
model. Additionally, the investigator focused on the original data with data reported 
without outliers or recoded as detailed in Tables 30, 32, 34, and 36 and specified results 
section.  
There were minimal changes when adding the interleukins IL-6 and IL-8. There 
were no changes in the PASAT Trial 1 model, and semi-partial correlation effect sizes 
showed that Il-6 and IL-8 were non-meaningful. In regard to PASAT Trial 2, the only 
change was seen in the semi-partial correlation effect sizes in which high school 
education was now interpreted as small (.02), rather than non-significant. Lastly, the 
semi-partial correlation effect sizes for IL6 was non-meaningful and the IL-8 interleukin 
was interpreted as small. PASAT Trial 3 interpretation was changed as health condition 
and PTSD symptoms were interpreted as small via their semi-partial correlation effect 
sizes. However, IL-6 and IL-8 were non-meaningful in the final model. Lastly, the 
PASAT Trial 4 returned significance for the first Model (p = .045) which was previously 
non-significant. Additionally, semi-partial correlation effects sizes showed that IL-6 and 
IL-8 were non-meaningful.  




results. The most striking limitation is the small sample size especially considering the 
multiple analyses conducted. Therefore, effect sizes were utilized over an alpha level 
criterion as the study was likely underpowered and interpretation would have a higher 
risk for Type 2 errors. Additionally, the small sample size and use of measures limited 
the ability to truly investigate the differences between individuals with PTSD. The only 
measure of PTSD was a screening measure (i.e., DTS), which is not sufficient for a 
formal diagnosis, and therefore the score was used as a range of PTSD symptom severity. 
Additionally, this limited the available analyses for PTSD and GWI as a formal diagnosis 
of PTSD would have lent itself to a group analysis.  Therefore, this study cannot formally 
declare the etiology of cytokines given its association with GWI and PTSD. Another 
notable limitation is the use of one measure of attention and working memory. Additional 
differential measures of attention and working memory would have been beneficial to 
investigate if a similar trend was observed in both measures, especially given that 
neuropsychological measures can detect different trends solely on the method or task 
design. The PASAT also had notable limitations for this particular participant group 
being that age effects are seen after age 50 (Roman et al., 1991) , there is high correlation 
with educational attainment (Stuss et al., 1987), there is a small normative sample (n = 
80) from New Zealand (Gronwall & Wrightson, 1974), and there are notable practice 
effects (Gronwall, 1977). Another limitation is that interleukin measures included in the 
analysis were only at rest, as that was the only time the PASAT was administered. 
Therefore, the researcher is unable to make inferences based on what immunological 
markers would have been impacted during a stimulated hyperimmune response. 




exertion, gender, and other cytokines or hormones. The researcher attempted to control 
for these factors by including only men in her analysis and cytokines were interpreted at 
rest. However, it may have been beneficial to investigate the connection between cortisol 
given the connection between the HPA axis and cytokines (Craddock et al., 2014). 
Strengths. Strengths of the study include the control of heavily influential factors 
and the investigation of a more objective measure of immunological function over 
heterogenous diagnostic categories for GWI. Specifically, age and education level were 
controlled for in each analysis especially given that these are known to impact PASAT 
functioning. Additionally, several studies of GWI are limited in that toxin exposure is 
based on self-report of toxin exposure or plume analysis which rely on retrospective 
techniques. The inclusion of cytokines in the analysis enabled the investigator to observe 
immunological deficits at the time of test administration and therefore, was able to 
demonstrate consistent patterns of dysfunction despite the large gap of time between the 
Gulf War and the study. The impact of GWI and cytokines also remained significant even 
with the inclusion of PTSD severity, which helped support the argument towards an 
underlying biological process over a purely somatic or psychological one.  
The use of the PASAT also had several strengths it that it was a measure with 
high consistency (Cronbach’s alpha = .90; Crawford, Obansawini, & Allan, 1998) and 
reliability (r = .83-.96; Sjogren, Thomsen, & Olsen, 2000). Additionally, the measure 
showed good convergent validity (Deary, Langan, Hepburn, & Frier, 1991; Gronwall & 
Wrightson, 1981; Sherman, Strauss, & Spellacy, 1997; Schachinger, Cox, Linder, Brody, 
& Keller, 2003) and construct validity (Larrabee & Curtiss, 1995). Lastly, this measure 




found many individuals exhibit signs of fatigue towards the last two trials of the task. 
However, Johnson et al. (1997) found that there were no fatigue effects even with four re-
administrations of the task. 
Future Directions. This study points towards potential attention or working 
memory difficulties in veterans with GWI and PTSD symptoms alongside imbalanced 
levels of certain cytokines. Results of this study would be bolstered with the use of more 
validated measures of attention and working memory. Additionally, it would be helpful to 
investigate a cytokine profile with a full neuropsychological battery to better understand 
the full profile of neuropsychological deficits associated with GWI and PTSD. 
Furthermore, it remains unclear what aspects of immunological dysfunction are linked to 
neuropsychological deficits. Repetition of these analyses can show a clearer pattern of 
biomarkers associated with cognitive symptoms in GWI and PTSD and point towards a 
specific etiology to better assist diagnosis and treatment.  
Another suggestion for future research is the use of more validated measures of 
PTSD such as the CAPS when investigating neuropsychological performance in 
conjunction with immunological markers. These investigations would further clarify what 
cytokines contribute uniquely to GWI and PTSD and its individual influence on cognitive 
measures, which would further benefit neuropsychologists examining a patient with 
potential GWI symptoms. 
Conclusions 
In general, the results are somewhat consistent with prior literature pointing 
towards problems with attention and working memory (i.e., learning) in GWI. These 




one measure; however, the utility of the GWI diagnosis is questionable once other 
variables are added, especially interleukin. However, these results also did not support 
the literature that pointed towards a specific psychological etiology in GWI as PTSD as a 
factor did not appear to meaningfully contribute to the task performance except during 
the last and hardest trial. Therefore, PTSD symptoms may only play a factor during 
higher task demands regarding attention and working memory. Overall, this study was 
able to contribute to the literature of GWI showing the role of cytokines across trials of a 
working and memory task, in conjunction with a GWI and PTSD diagnosis.  
Of note, how cytokines are activated and what role they play in attention and 
working memory remains to be seen in this study. As GWI and PTSD both are associated 
with overactive body states, these cytokines could be linked to either condition. 
Therefore, more rigorous attention to PTSD as a diagnosis is imperative to elucidate these 
patterns when investigating cytokine levels. This research should also be conducted with 
awareness that cytokines are sensitive to so many other aspects including gender of the 
participant, time of day, and level of exertion.  
Finally, this study showed a pattern using only one measure of attention and 
working memory and would have benefitted from a full neuropsychological battery. 
However, the study did show that cytokines were associated with changes in 
performance, which gives credence to the study of cytokines in neuropsychological 
batteries especially in conditions known to impact neurological systems. Additionally, a 
pattern towards a certain immunological pattern does lend a more biological lean towards 
GWI and PTSD, which may open more treatment and diagnostic avenues for future 
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Major Depressive Disorder    MDD 
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Positive Affect/Negative Schedule   PANS 
Post-Traumatic Stress Disorder   PTSD 
Post Traumatic Stress Disorder Checklist    PCL 
Profile of Mood States    POMS 
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Rey Auditory Verbal Learning Test   RAVLT 
Rey-Osterrieth Complex Figure Test   ROCF 
State-Trait Anger Expression Inventory   STAEI 
State-Trait Anxiety Inventory    STAI 
Structural Clinical Interview for DSM   SCID 





Sustained Attention to Response Task   SART 
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Test of Memory Malingering    TOMM 
Trail Making Test    TMT 
Weschler Adult Intelligence Scale-Revised    WAIS-R 
Weschler Adult Intelligence Scale- Third Edition  WAIS-III 
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Con 1                                               
Age .1 1                                             
HS -.1 -.3 1                                           
Col .2 .1 -.7 1                                         
Doc -.2 .2 -.3 -.4 1                                       
TrSx .8* .3 -.2 .3 -.2 1                                     
PT1 -.2 -.2 .1 -.2 .3 -.2 1                                   
PT2 -.3 -.2 .1 -.2 .3 -.3 .9 1                                 
PT3 -.2 -.3 .3 -.3 .2 -.3 .8 .9 1                               
PT4 -.3 -.2 .3 -.3 .2 -.3 .7 .7 .9 1                             
IL1a .1 .1 -.0 .1 -.1 .1 -.1 -.2 -.2 -.2 1                           
IL1b .1 .1 -.2 .1 .1 .2 -.1 -.2 -.2 -.3 .4 1                         
IL2 -.1 .2 -.1 .2 -.1 -.1 -.2 -.2 -.2 -.1 .0 .0 1                       
IL4 -.2 .0 .1 .0 -.1 -.1 .1 .1 .1 .1 .0 -.1 .8 1                     
IL5 .0 .1 -.2 .2 -.1 .1 -.3 -.3 -.3 -.2 .7* .3 .6 .6 1                   
IL6 .1 .2 -.2 .3 -.1 .1 -.3 -.3 -.4 -.3 .7 .3 .6 .5 1 1                 
IL8 .3 -.0 -.0 -.1 .1 .3 -.3 -.4 -.4 -.3 .4 .5* .3 .1 .5 .5 1               
IL10 -.4 .3 .0 .1 -.1 -.3 -.2 -.1 -.1 -.0 .3 .3 .7 .6 .5 .5 .1 1             
IL12 -.1 -.0 -.1 .2 -.1 -.2 -.0 .0 -.0 .1 -.0 -.0 .6 .7 .4 .3 .0 .5 1           
IL13 .0 .1 -.1 .2 -.1 .1 -.2 -.3 -.3 -.2 .4 .2 .9 .7 .9 .9 .5 .6 .5 1         
IL15 -.1 .1 -.1 .1 .0 -.0 -.2 -.3 -.3 -.3 .6 .7 .2 .1 .5 .5 .7 .4 .2 .4 1       
IL17 -.2 .2 -.1 .2 -.0 -.1 -.3 -.3 -.2 -.1 .1 -.0 .7 .5 .6 .6 .1 .5 .3 .7 .1 1     
IL23 -.1 .0 -.3 .2 .0 -.2 -.1 -.0 -.1 -.0 -.1 .0 .7 .5 .5 .5 -.0 .4 .7 .6 .1 .6 1   
IFNy -.0 .0 -.1 .0 .2 .1 -.3 -.4 -.4 -.3* .3 .5 .3 .1 .5 .5 .8 .3 .2 .5 .8 .1 .1 1 
TNFa .0 .1 -.1 .1 .0 .1 -.3 -.3 -.4 -.3 .8 .7 .2 .1 .7 .7 .7 .4 .1 .5 .9 .2 .1 .8 
Note: *Bolded indicated significant values. Con = Condition, HS = High School, Col = College, Doc = Doctorate, TrSx = PTSD Symptoms, PT1 = 
PASAT Trial 1, PT2 = PASAT Trial 2, PT3 = PASAT Trial 3, PT4 = PASAT Trial 4, IL1a = Interleukin 1a, IL1b = Interleukin 1b, IL2 = Interleukin 2, 
IL4 = Interleukin 4, IL5 = Interleukin 5, IL6 = Interleukin 6, IL8 = Interleukin 8, IL10 = Interleukin 10, IL12 = Interleukin 12, IL13 = Interleukin 13, 






Literature Review Summary 
 
First Author (Year) N Age Education  GWI? Primary Significant Outcomes 
Axelrod (1997) 44 33.3 13.5 No Grooved Pegboard, Stroop, MMPI  
Sillanpaa (1997) 49 33.59 13.47 No  Regression Model of Affective Symptoms  
Proctor (2003) 215 38.8 Not Reported No POMS 
White (2001) 240 
D = 53.8, ND = 
41.0 
D = 13.7  
ND  = 13.7 No POMS, CPT 
David (2002) 341 See reference See reference Yes MPS  
Wallin (2009) 41 
GWI = 34.5 
HC = 30.4 See reference Yes PAI, SF-36 
Hom (1997) 46 
GWI = 47.81 
HC = 47.95 
GWI mean = 11.92 
HC mean = 12.50 Yes 
HII, FSIQ, Weschler VI, Perceptual-Motor 
Intelligence, CT, TMT (Trails B), Motor Tests, 
WAIS-V, WAIS- Comprehension, PAI  
Anger (1999) 101 
Cases = 32.6 
Controls = 30.6 
Cases  = 13.5  
Controls = 13.8  Yes 
Psych, ODTP, Symbol Digit, Simple  Reaction Time, 
Digit Span  
Lange (2001) 87 
Healthy = 34.3 
GWI = 35.5 Not reported  Yes 
PASAT, Category Test, NES SRT  
Category Test  
Proctor (2006) 140 See reference  See reference  No PP, Block Designs 
Janulewicz (2017) 14 Not reported Not reported No  
Block Designs, Digit Span, TMT, CVLT, CP,  
 
Vasterling (1998) 43 
Healthy = 35.3 
PTSD = 36.3 
Healthy = 14.6 
PTSD = 13.8 No 
Arithmetic, CPT, RAVLT, Continuous Visual 
Memory Test  
Lindem (2003) 240 
GW = 34.9 
Germany = 41.0 
GW = 13.9 
Germany = 13.7 No 
WAIS-R Information, CPT, FTT, PP, CVLT, WMS 
Visual Reproduction, POMS 
Sullivan (2003) 260 
GW-D= 35.6 
 Non-GW-D = 
30.8 
GW-D = 13.4 
 Non-GW-D = 13.9 No 
Digit Span, Block Design, Visual Reproduction, 
ROCF, POMS, TOMM, WCST 
Sullivan (2018) 159 See reference See reference  Yes CPT, ROCF  
 
 
